As
filed with the Securities and Exchange Commission on October 17, 2023
Registration
No. 333-
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
S-3
REGISTRATION
STATEMENT
UNDER
THE
SECURITIES ACT OF 1933
Notable
Labs, Ltd.
(Exact
name of registrant as specified in its charter)
Israel |
|
2834 |
|
Not
Applicable |
(State
or other jurisdiction of
incorporation or organization) |
|
(Primary
Standard Industrial
Classification
Code Number) |
|
(I.R.S.
Employer
Identification Number) |
320
Hatch Drive
Foster
City, CA 94404
(415)
851-2410
(Address,
including zip code, and telephone number, including area code, of registrant’s principal executive offices)
Thomas
Bock
President
and Chief Executive Officer
Notable
Labs, Ltd.
320
Hatch Drive
Foster
City, CA 94404
(415)
851-2410
(Name,
address, including zip code, and telephone number, including area code, of agent for service)
Copies
to:
Michael
E. Mariani, Esq.
Matthew
G. Jones, Esq.
Cravath,
Swaine & Moore LLP
825
Eighth Avenue
New
York, NY 10019
(212)
474-1000 |
|
Evan
Kipperman, Esq.
Michael
Grundei, Esq.
Elishama
Rudolph, Esq.
Wiggin
and Dana LLP
281
Tresser Boulevard, 14th Floor
Stamford,
CT 06901
(203)
363-7600 |
Approximate
date of commencement of proposed sale to the public:
From
time to time after this registration statement becomes effective, as determined by market conditions and other factors.
If
the only securities being registered on this form are being offered pursuant to dividend or interest reinvestment plans, please check
the following box. ☐
If
any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the
Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following
box. ☒
If
this form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the
following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering. ☐
If
this form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
If
this form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective
upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐
If
this form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional
securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐
Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,”
“smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large
accelerated filer ☐ |
|
Accelerated
filer ☐ |
|
Non-accelerated
filer ☒ |
|
Smaller
reporting company ☒ |
|
Emerging
growth company ☐ |
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
The
Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the
Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective
in accordance with Section 8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on such date
as the Commission, acting pursuant to said Section 8(a), may determine.
The
information in this prospectus is not complete and may be changed. These securities may not be sold until the registration statement
filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell the securities and it is not
soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.
SUBJECT
TO COMPLETION
DATED
OCTOBER 17, 2023
PROSPECTUS
Notable
Labs, Ltd.
$100,000,000
Ordinary
Shares
Warrants
Units
We
may offer under this prospectus from time to time, at prices and on terms to be determined by market conditions at the time we make the
offer, up to an aggregate of $100,000,000 of our:
|
● |
ordinary
shares; |
|
|
|
|
● |
warrants
to purchase ordinary shares; or |
|
|
|
|
● |
any
combination of the above, separately or as units. |
We
refer to our ordinary shares, warrants and units, collectively as “securities” in this prospectus.
This
prospectus may not be used to sell our securities unless accompanied by a prospectus supplement. Before you invest in our securities,
you should carefully read both this prospectus and the prospectus supplement related to the offering of the securities.
Our
ordinary shares are listed on The Nasdaq Capital Market under the symbol “NTBL.” The last reported sale price of our ordinary
shares on October 17, 2023 on The Nasdaq Capital Market was $4.49 per share. We have not yet determined whether any of
the other securities that may be offered by this prospectus will be listed on any exchange, inter-dealer quotation system or over-the-counter
market. If we decide to seek listing of any such securities, a prospectus supplement relating to those securities will disclose the exchange,
quotation system or market on which the securities will be listed.
If
we sell securities through agents or underwriters, we will include their names and the fees, commissions and discounts they will receive,
as well as the net proceeds to us, in the applicable prospectus supplement.
Effective
as of October 16, 2023, we filed an amendment to our amended and restated articles of association to effect (i) an increase to our registered
share capital by NIS 10,000,000 and the creation of an additional 1,000,000,000 ordinary shares and (ii) a reverse share split of our
issued and outstanding ordinary shares by a ratio of 35 to 1. Except as otherwise indicated, all share and per share prices in
this prospectus have been adjusted to reflect the reverse share split and the share capital increase. Following the reverse share split,
our authorized share capital is NIS 12,000,000 divided into 34,285,714 ordinary shares, par value NIS 0.35 per share. Immediately
following the closing of the Merger (as defined below), there were approximately 8,963,501 of our ordinary shares outstanding.
The
securities offered hereby involve a high degree of risk. See “Risk Factors” on page 5 of this prospectus and in our most
recent Annual Report on Form 10-K and in our Registration Statement on Form S-4 (File No. 333-271826), filed with the U.S. Securities
and Exchange Commission (the “SEC”) on May 11, 2023, as amended (the “Form S-4”), which are incorporated by reference
in this prospectus, as well as the risk factors that are incorporated by reference into this prospectus from any other filing we make
with the SEC and any amendment or supplement to this prospectus.
None
of the U.S. Securities and Exchange Commission, the Israeli Securities Authority or any state or other foreign securities commission
have approved or disapproved of these securities or passed upon the adequacy, completeness or accuracy of this prospectus. Any representation
to the contrary is a criminal offense.
The
date of this prospectus is , 2023.
TABLE
OF CONTENTS
Prospectus
About
This Prospectus
This
prospectus is part of a shelf registration statement that we filed on Form S-3 with the U.S. Securities and Exchange Commission (the
“SEC”), under the Securities Act of 1933, as amended (the “Securities Act”).
Under
this shelf registration process, we may offer the securities described in this prospectus from time to time at prices and on terms to
be determined by market conditions at the time of offering. This prospectus provides you with a general description of the securities
we may offer. Each time we offer a type or series of securities, we will provide a prospectus supplement that will describe the specific
amounts, prices and other important terms of the securities, to the extent applicable.
Registration
of the securities covered by this prospectus does not mean that these securities will necessarily be offered or sold. As of the date
of filing this registration statement, we have no specific plans for selling the securities registered hereunder.
A
prospectus supplement may include a discussion of risks or other special considerations applicable to us or the offered securities. A
prospectus supplement or any free writing prospectus may also add, update or change information in this prospectus. If there is any inconsistency
between the information in this prospectus and the applicable prospectus supplement, you must rely on the information in the prospectus
supplement. Please carefully read both this prospectus, including the information incorporated by reference into this prospectus, and
the applicable prospectus supplement or any free writing prospectus together with additional information incorporated by reference herein
as described under the heading “Where You Can Find More Information.” This prospectus may not be used to offer or sell any
securities unless accompanied by a prospectus supplement.
The
registration statement containing this prospectus, including the exhibits to the registration statement, provides additional information
about us and the securities offered under this prospectus. The registration statement can be read at the SEC website mentioned under
the heading “Where You Can Find More Information.”
We
may sell the securities directly to or through underwriters, dealers or agents. We and our underwriters or agents reserve the right to
accept or reject all or part of any proposed purchase of securities. If we do offer securities through underwriters or agents, we will
include in the applicable prospectus supplement:
|
● |
the
names of those underwriters or agents; |
|
|
|
|
● |
applicable
fees, discounts and commissions to be paid to them; |
|
|
|
|
● |
details
regarding over-allotment options, if any; and |
|
|
|
|
● |
the
net proceeds to us. |
We
have not authorized any broker-dealer, salesperson or other person to give any information or to make any representation other than those
contained or incorporated by reference in this prospectus and the accompanying supplement to this prospectus. You must not rely upon
any information or representation not contained or incorporated by reference in this prospectus or the accompanying prospectus supplement.
This prospectus and the accompanying prospectus supplement do not constitute an offer to sell or the solicitation of an offer to buy
securities, nor do this prospectus and the accompanying prospectus supplement constitute an offer to sell or the solicitation of an offer
to buy securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation. The information contained
in this prospectus and the accompanying prospectus supplement speaks only as of their respective dates and may not reflect subsequent
changes in our business, financial condition, results of operations and prospects even though this prospectus and any accompanying prospectus
supplement is delivered or securities are sold on a later date.
We
own various trademark registrations and applications, and unregistered trademarks, including our corporate logo. All other trade names,
trademarks and service marks of other companies appearing in this prospectus are the property of their respective holders. Solely for
convenience, the trademarks and trade names in this prospectus may be referred to without the ® and ™
symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent
under applicable law, their rights thereto. We do not intend to use or display other companies’ trademarks and trade names to imply
a relationship with, or endorsement or sponsorship of us by, any other companies.
This
prospectus includes summaries of certain provisions contained in some of the documents described herein, but reference is made to the
actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some
of the documents referred to herein have been filed, will be filed or are incorporated by reference as exhibits to the registration statement
of which this prospectus is a part, and you may obtain copies of those documents as described under the heading “Where You Can
Find More Information.”
Unless
otherwise indicated or the context otherwise requires, the terms “Notable,” “NTBL,” “we,” “our,”
“the Company” and “us” refer to Notable Labs, Ltd., an Israeli corporation, and its consolidated subsidiaries.
Notable Labs, Ltd. was formerly known as Vascular Biogenics Ltd. prior to its name change on October 16, 2023, and accordingly, unless
otherwise specified or the context requires otherwise, (i) references in this prospectus and the documents incorporated by reference
herein to Vascular Biogenics Ltd., VBL or the combined organization refer to Notable Labs, Ltd. and (ii) reference in the documents incorporated
by reference herein to Notable refer to Notable Labs, Inc., a Delaware corporation, which, upon consummation of the Merger (as defined
below) became a wholly owned subsidiary of Notable Labs, Ltd.
Prospectus
Summary
The
following summary highlights selected information contained or incorporated by reference elsewhere in this prospectus and does not contain
all of the information that you should consider in deciding whether or not you should invest in any of our securities. Before investing
in our securities, you should carefully read this entire prospectus, the applicable prospectus supplement and any related free writing
prospectus, including the information under the caption “Risk Factors” herein and the applicable prospectus supplement and
under similar headings in the other documents that are incorporated by reference into this prospectus, including our most recent annual
report on Form 10-K on file with the SEC and any amendments thereto. You should also carefully read the other information incorporated
by reference into this prospectus, including our financial statements and the related notes, and the exhibits to the registration statement
of which this prospectus is a part.
Company
Overview
Notable
Labs, Ltd., formerly known as Vascular Biogenics Ltd., is a clinical-stage platform therapeutics company developing predictive precision
medicines for patients with cancer. Through its proprietary Predictive Precision Medicines Platform (“PPMP”), Notable bio-simulates
a cancer treatment to predict whether or not a patient is likely to respond to that specific therapeutic. Notable’s PPMP is designed
to identify and select patients expected to be clinically responsive prior to their treatment and thus potentially enable fast-track
clinical development in this patient population. By working to advance and expand the reach of the PPMP across diseases and predicted
medical outcomes, Notable aims to be the leader in precision medicine and revolutionize the way patients seek and receive treatments
that work best for them – patient by patient and cancer by cancer. Notable believes it has created a targeted in-licensing and
development or co-development strategy for investigational compounds that have shown clinical activity to deliver a product’s medical
impact and commercial value faster, higher, and with a greater likelihood of success when compared with traditional drug development.
Although the performance of Notable’s PPMP has demonstrated success in predicting the outcome of approved, standard of care agents,
the development of investigational therapies such as volasertib utilizing the PPMP still carries substantial risks, including Notable’s
limited experience in drug discovery and development, and the platform may never result in the regulatory approval of a drug candidate
or do so with greater speed, value or success. Furthermore, clinical response alone does not guarantee that Notable’s product candidates
will demonstrate clinical efficacy or that they will prove to be safe as required to receive FDA or similar regulatory approval. For
a further description of Notable’s business as of the date of this prospectus, see the section “Notable Business” in
the Form S-4.
Company
Information
On
February 22, 2023, the Company, then known as Vascular Biogenics Ltd., entered into an Agreement and Plan of Merger (the
“Merger Agreement”) with Notable Labs, Inc., a Delaware corporation (“Old Notable”), and Vibrant Merger Sub,
Inc., a direct, wholly-owned subsidiary of the Company (“Merger Sub”), pursuant to which, and subject to the satisfaction
or waiver of the conditions set forth in the Merger Agreement, Old Notable would be merged with and into Merger Sub, with Old Notable
continuing as the surviving corporation and a wholly-owned subsidiary of the Company (the “Merger”).
Prior
to the closing of the Merger, Vascular Biogencis Ltd. had one product candidate, VB-601, which is a targeted antibody for immune-inflammatory
applications. On October 16, 2023, the Company completed the sale of VB-601 and MOSPD2 related assets (the “VB-601 Asset”)
to Immunewalk Therapeutics Inc. (“Immunewalk”), pursuant to the terms of an Asset Purchase Agreement dated as
of October 1, 2023, between the Company and Immunewalk (the “Asset Purchase Agreement”). Under the Asset Purchase
Agreement, Immunewalk agreed to pay an upfront cash payment of $250,000 to the Company at the closing and additional payments of up to
$4.75 million upon the achievement of clinical and commercial milestones by Immunewalk, its Affiliates (as defined therein) or Licensees
(as defined therein), plus additional royalties on the terms set forth in the Asset Purchase Agreement.
On
October 16, 2023, Notable announced the closing of the Merger. At the closing of the Merger, each outstanding share of Old Notable’s
common stock converted into the right to receive Vascular Biogencis Ltd.’s ordinary shares at an exchange ratio of 0.0629
ordinary shares of Vascular Biogenics Ltd. for each share of common stock of Old Notable. Immediately following the closing of the Merger,
there were approximately 8,963,501 ordinary shares of Notable outstanding, with pre-Merger Vascular Biogenics Ltd. shareholders
owning approximately 75.2% and pre-Merger Old Notable stockholders owning approximately 24.8% of the outstanding ordinary
shares of Notable, respectively. Effective upon the closing of the Merger, Vascular Biogenics Ltd. was renamed “Notable
Labs, Ltd.” and its ordinary shares are currently trading on The Nasdaq Capital Market under the symbol “NTBL.”
Prior
to the closing of the Merger, Vascular Biogenics Ltd. was out of compliance with The Nasdaq Stock Market LLC’s (“Nasdaq”)
minimum bid price requirement pursuant to Nasdaq Listing Rule 5550(a)(2). On October 9, 2023, the Nasdaq Hearings Panel issued its decision
(the “Decision”) to grant Vascular Biogenics Ltd. a temporary exception to regain compliance with Nasdaq Listing Rule 5550(a)(2).
The Decision required, among other things, that Vascular Biogenics Ltd. demonstrate compliance with the minimum bid price requirement
for initial listing and satisfy all other requirements for initial listing on Nasdaq. While Notable expects to comply with each of these
requirements following the closing of the Merger, there can be no assurance that Notable will meet Nasdaq’s initial listing requirements.
Our
principal executive office is located at Notable Labs, Ltd., 320 Hatch Drive, Foster City, CA 94404 and our telephone number is (415)
851-2410. Our internet address is www.notablelabs.com. The information contained on, or that can be accessed through, our website is
neither a part of nor incorporated into this prospectus. We have included our website address in this prospectus solely as an inactive
textual reference.
Risk
Factors (see page 5)
We
are subject to various risks associated with our business and our industry. These risks include the following:
|
● |
Prior
to the closing of the Merger, Vascular Biogenics Ltd. has never generated any revenue from product sales and Old Notable has generated
only limited revenue since inception, and the combined organization may never be profitable; |
|
|
|
|
● |
The
Company’s failure to meet the continued listing requirements of The Nasdaq Capital Market could result in a delisting of the
Company’s ordinary shares; |
|
|
|
|
● |
If
the Company is unable to generate successful results from clinical studies of its product candidates, or experiences significant
delays in doing so, its business may be materially harmed; |
|
|
|
|
● |
The
Company’s product candidates may exhibit undesirable side effects when used alone or in combination with other approved pharmaceutical
products or investigational new drugs, which may delay or preclude further development or regulatory approval, or limit their use
if approved; |
|
|
|
|
● |
The
Company may not be successful in its efforts to identify or discover potential product candidates; |
|
|
|
|
● |
Even
if the Company completes the necessary preclinical studies and clinical trials, it cannot predict whether or when it will obtain
regulatory approval to commercialize a product candidate; |
|
|
|
|
● |
The
Company faces significant competition from other biotechnology, therapeutics and pharmaceutical companies and its operating results
will suffer if it fails to compete effectively; |
|
|
|
|
● |
The
commercial success of the Company’s product candidates will depend upon the acceptance of these product candidates by the medical
community, including physicians, patients and healthcare payors; |
|
|
|
|
● |
If
the Company fails to comply with health and safety laws and regulations, it could incur costs that could have a material adverse
effect on the success of its business; |
|
|
|
|
● |
The
Company relies on third-party manufacturers to produce the supply of the Company’s preclinical product candidates, and the
Company intends to rely on third parties to produce future clinical supplies of product candidates that the Company advances into
clinical trials and commercial supplies of any approved product candidates; |
|
|
|
|
● |
If
the Company is unable to obtain or protect intellectual property rights related to its current and future products and product candidates
and trade secrets, it may not be able to compete effectively in its markets; |
|
|
|
|
● |
Recent
and future healthcare legislation may further impact the Company’s business operations; |
|
|
|
|
● |
The
Company’s stock price is expected to be volatile, and the market price of its ordinary shares may drop following the Merger; |
|
|
|
|
● |
The
Company will need to raise additional financing in the future to fund its operations, which may not be available to it on favorable
terms or at all; and |
|
|
|
|
● |
The
Company’s management will have limited public company experience and will be subject to additional regulatory compliance requirements
that must be managed effectively. |
Risk
Factors
An
investment in our securities is speculative and involves a high degree of risk. Therefore, you should not invest in our securities unless
you are able to bear a loss of your entire investment. You should carefully consider the risk factors described under the heading “Risk
Factors” in the Form S-4, our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q or Current
Reports on Form 8-K, which are incorporated by reference in this prospectus, and in subsequent reports that we file with the SEC. You
should carefully consider these risks together with the other information contained or incorporated by reference in this prospectus before
deciding to invest in our securities. If any of these risks actually occur, our business, financial condition, results of operations
and prospects could be materially and adversely affected. In that case, the trading price of our securities could decline, and you may
lose all or part of your investment.
Note
Concerning Forward-Looking Statements
The
statements incorporated by reference or contained in this prospectus discuss our future expectations, contain projections of our results
of operations or financial condition, and include other forward-looking information within the meaning of Section 27A of the Securities
Act. You should not unduly rely on forward-looking statements contained or incorporated by reference in this prospectus. Our actual results
and performance may differ materially from those expressed in such forward-looking statements. Forward-looking statements that express
our beliefs, plans, objectives, assumptions, future events or performance may involve estimates, assumptions, risks and uncertainties.
Such risks and uncertainties are discussed in this prospectus under the heading “Risk Factors,” and in our other filings
with the SEC. You should read and interpret any forward-looking statements together with these documents. Forward-looking statements
often, although not always, include words or phrases such as the following: “will likely result,” “are expected to,”
“will continue,” “is anticipated,” “estimate,” “intends,” “plans,” “projection”
and “outlook.”
All
statements other than statements of historical fact are statements that could be deemed forward-looking statements. For example, forward-looking
statements include any statements of the plans, strategies and objectives of management for future operations, including the execution
of integration and restructuring plans and the anticipated timing of filings; any statements concerning proposed new products, services
or developments; any statements regarding future economic conditions or performance; statements of belief and any statement of assumptions
underlying any of the foregoing.
In
addition, statements that “we believe,” “Notable believes” and similar statements are based upon information
available as of the date of this prospectus, and while we believe such information forms a reasonable basis for such statements, such
information may be limited or incomplete, and such statements should not be read to indicate that we have conducted an exhaustive inquiry
into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned
not to unduly rely upon these statements.
If
any of these risks or uncertainties materializes or any of these assumptions proves incorrect, the results of the Company could differ
materially from the forward-looking statements. All forward-looking statements in this prospectus are current only as of the date on
which the statements were made. We do not undertake any obligation to publicly update any forward-looking statement to reflect events
or circumstances after the date on which any statement is made or to reflect the occurrence of unanticipated events, except as required
by applicable law.
Selected
Financial Data
On
October 16, 2023, we effected a reverse share split of our issued and outstanding ordinary shares by a ratio of 35 to 1. Following the
reverse share split, our authorized share capital is NIS 12,000,000 divided into 34,285,714 ordinary shares, par value NIS 0.35 per share.
Any fraction of an ordinary share that would otherwise have resulted from the reverse share split was rounded up to the next whole number.
The
following selected financial data has been derived from our historical audited financial statements included in our Annual Report on
Form 10-K filed with the SEC on March 14, 2023, and our historical unaudited financial statements included in our Quarterly Reports on
Form 10-Q filed with the SEC on May 15, 2023 and August 14, 2023, each of which is incorporated by reference herein, as adjusted to reflect
the 35-to-1 reverse share split for all periods presented (but does not otherwise give pro forma effect to the Merger and does not, for
the avoidance of doubt, take into account any of the results of operations of Old Notable for the periods presented).
As
reported
| |
Year Ended December 31, | |
| |
2022 | | |
2021 | |
| |
U.S. dollars in thousands | |
Net loss and comprehensive loss | |
$ | 32,304 | | |
$ | 29,920 | |
| |
U.S.
dollars | |
Net loss per ordinary share | |
| | | |
| | |
Basic and diluted | |
$ | 0.42 | | |
$ | 0.45 | |
| |
| | | |
| | |
| |
Number
of shares | |
Weighted average ordinary shares outstanding | |
| | | |
| | |
Basic and diluted | |
| 77,554,740 | | |
| 66,346,506 | |
| |
Three Months Ended March 31, | |
| |
2023 | | |
2022 | |
| |
U.S. dollars in thousands | |
Net loss and comprehensive loss | |
$ | 2,639 | | |
$ | 10,428 | |
| |
U.S.
dollars | |
Loss per ordinary share | |
| |
Basic and diluted | |
$ | 0.03 | | |
$ | 0.13 | |
| |
| | | |
| | |
| |
Number
of shares | |
Weighted average ordinary shares outstanding | |
| | | |
| | |
Basic and diluted | |
| 77,800,117 | | |
| 77,386,967 | |
| |
Three Months Ended June 30, | | |
Six Months Ended June 30, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
| |
U.S. dollars in thousands | | |
U.S. dollars in thousands | |
Net loss and comprehensive loss | |
$ | 874 | | |
$ | 9,434 | | |
$ | 3,513 | | |
$ | 19,862 | |
| |
U.S.
dollars | | |
U.S.
dollars | |
Loss per ordinary share | |
| | | |
| | | |
| | | |
| | |
Basic and diluted | |
$ | 0.01 | | |
$ | 0.12 | | |
$ | 0.04 | | |
$ | 0.26 | |
| |
| | | |
| | | |
| | | |
| | |
| |
Number
of shares | | |
Number
of shares | |
Weighted average ordinary shares outstanding | |
| | | |
| | | |
| | | |
| | |
Basic and diluted | |
| 78,393,524 | | |
| 77,398,939 | | |
| 78,098,460 | | |
| 77,392,922 | |
As
adjusted for 35 to 1 reverse share split
| |
Year Ended December 31, | |
| |
2022 | | |
2021 | |
| |
U.S. dollars in thousands | |
Net loss and comprehensive loss | |
$ | 32,304 | | |
$ | 29,920 | |
| |
U.S.
dollars | |
Loss per ordinary share | |
| | | |
| | |
Basic and diluted | |
$ | 14.58 | | |
$ | 15.78 | |
| |
| | | |
| | |
| |
Number
of shares | |
Weighted average ordinary shares outstanding | |
| | | |
| | |
Basic and diluted | |
| 2,215,850 | | |
| 1,895,614 | |
| |
Three Months Ended March 31, | |
| |
2023 | | |
2022 | |
| |
U.S. dollars in thousands | |
Net loss and comprehensive loss | |
$ | 2,639 | | |
$ | 10,428 | |
| |
U.S.
dollars | |
Loss per ordinary share | |
| | | |
| | |
Basic and diluted | |
$ | 1.19 | | |
$ | 4.72 | |
| |
| | | |
| | |
| |
Number
of shares | |
Weighted average ordinary shares outstanding | |
| | | |
| | |
Basic and diluted | |
| 2,222,860 | | |
| 2,211,056 | |
| |
Three Months Ended June 30, | | |
Six Months Ended June 30, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
| |
U.S. dollars in thousands | | |
U.S. dollars in thousands | |
Net loss and comprehensive loss | |
$ | 874 | | |
$ | 9,434 | | |
$ | 3,513 | | |
$ | 19,862 | |
| |
U.S.
dollars | | |
U.S.
dollars | |
Loss per ordinary share | |
| | | |
| | | |
| | | |
| | |
Basic and diluted | |
$ | 0.39 | | |
$ | 4.27 | | |
$ | 1.57 | | |
$ | 8.98 | |
| |
| | | |
| | | |
| | | |
| | |
| |
Number
of shares | | |
Number
of shares | |
Weighted average ordinary shares outstanding | |
| | | |
| | | |
| | | |
| | |
Basic and diluted | |
| 2,239,815 | | |
| 2,211,398 | | |
| 2,231,384 | | |
| 2,211,226 | |
Use
of Proceeds
Unless
we state otherwise in a prospectus supplement, we will use the net proceeds from the sale of securities under this prospectus for general
corporate purposes. From time to time, we may evaluate the possibility of acquiring businesses, products, equipment tools and technologies,
and we may use a portion of the proceeds as consideration for such acquisitions. Until we use net proceeds for these purposes, we may
invest them in interest-bearing securities.
Description
of Share Capital
General
Our
authorized share capital consists solely of 34,285,714 ordinary shares, par value NIS 0.35 per share, with approximately 8,963,501 ordinary
shares outstanding as of October 16, 2023. All of our outstanding ordinary shares are validly issued, fully paid and non-assessable.
Our ordinary shares are not redeemable and do not have any preemptive rights.
Registration
Number and Purpose of the Company
Our
registration number with the Israeli Registrar of Companies (“IROC”) is 51-289976-6. Our purpose as set forth in our amended
and restated articles of association is to engage in any lawful activity.
Voting
Rights and Conversion
All
ordinary shares will have identical voting and other rights in all respects.
Transfer
of Shares
Our
fully paid ordinary shares are issued in registered form and may be freely transferred under our amended and restated articles of association,
unless the transfer is restricted or prohibited by another instrument, applicable law or the rules of a stock exchange on which the shares
are listed for trade. The ownership or voting of our ordinary shares by non-residents of Israel is not restricted in any way by our amended
and restated articles of association or the laws of the State of Israel, except for ownership by nationals of some countries that are,
or have been, in a state of war with Israel.
Election
of Directors
Our
ordinary shares do not have cumulative voting rights for the election of directors. As a result, the holders of a majority of the voting
power present and voting at a shareholders meeting have the power to elect all of our directors, subject to the special approval requirements
for external directors.
Under
our amended and restated articles of association, our board of directors must consist of not less than three, not including two external
directors, but no more than nine directors (including the external directors). Pursuant to our amended and restated articles of association,
other than the external directors, for whom special election requirements apply under the Israeli Companies Law 5759-1999 (the “Companies
Law”), the vote required to appoint a director is a simple majority vote of holders of our voting shares, participating and voting
at the relevant meeting. Each director will serve until his or her successor is duly elected and qualified or until his or her earlier
death, resignation or removal by a vote of the majority voting power of our shareholders at a general meeting of our shareholders or
until his or her office expires by operation of law, in accordance with the Companies Law. In addition, our amended and restated articles
of association allow our board of directors to appoint directors to fill vacancies on the board of directors to serve for a term of office
equal to the remaining period of the term of office of the directors(s) whose office(s) have been vacated. External directors are elected
for an initial term of three years, may be elected for additional terms of three years each under certain circumstances, and may be removed
from office pursuant to the terms of the Companies Law.
Dividend
and Liquidation Rights
We
may declare a dividend to be paid to the holders of our ordinary shares in proportion to their respective shareholdings. Under the Companies
Law, dividend distributions are determined by the board of directors and do not require the approval of the shareholders of a company
unless the company’s articles of association provide otherwise. Our amended and restated articles of association do not require
shareholder approval of a dividend distribution and provide that dividend distributions may be determined by our board of directors.
Pursuant
to the Companies Law, the distribution amount is limited to the greater of retained earnings or earnings generated over the previous
two years, according to our then last reviewed or audited financial statements, provided that the date of the financial statements is
not more than six months prior to the date of the distribution, or we may otherwise only distribute dividends that do not meet such criteria
only with court approval. In each case, we are only permitted to distribute a dividend if our board of directors and the court, if applicable,
determines that there is no reasonable concern that payment of the dividend will prevent us from satisfying our existing and foreseeable
obligations as they become due.
In
the event of our liquidation, after satisfaction of liabilities to creditors, our assets will be distributed to the holders of our ordinary
shares in proportion to their shareholdings. This right, as well as the right to receive dividends, may be affected by the grant of preferential
dividend or distribution rights to the holders of a class of shares with preferential rights that may be authorized in the future.
Exchange
Controls
There
are currently no Israeli currency control restrictions on remittances of dividends on our ordinary shares, proceeds from the sale of
the shares or interest or other payments to non-residents of Israel, except for shareholders who are subjects of countries that are,
or have been, in a state of war with Israel.
Shareholder
Meetings
Under
Israeli law, we are required to hold an annual general meeting of our shareholders once every calendar year that must be held no later
than 15 months after the date of the previous annual general meeting. All meetings other than the annual general meeting of shareholders
are referred to in our amended and restated articles of association as extraordinary general meetings. Our board of directors may call
extraordinary general meetings whenever it sees fit, at such time and place, within or outside of Israel, as it may determine. In addition,
the Companies Law provides that our board of directors is required to convene an extraordinary general meeting upon the written request
of (i) any two of our directors or one-quarter of the members of our board of directors or (ii) one or more shareholders holding, in
the aggregate, either (a) 5% or more of our outstanding issued shares and 1% of our outstanding voting power or (b) 5% or more of our
outstanding voting power. One or more shareholders, holding 1% or more of the outstanding voting power, may ask the board to add an item
to the agenda of a prospective meeting, if the proposal merits discussion at the general meeting.
Subject
to the provisions of the Companies Law and the regulations promulgated thereunder, shareholders entitled to participate and vote at general
meetings are the shareholders of record on a date to be decided by the board of directors, which may be between four and 40 days prior
to the date of the meeting. Furthermore, the Companies Law requires that resolutions regarding the following matters must be passed at
a general meeting of our shareholders:
|
● |
amendments
to our articles of association; |
|
|
|
|
● |
appointment
or termination of our auditors; |
|
|
|
|
● |
appointment
of external directors; |
|
|
|
|
● |
approval
of certain related party transactions; |
|
|
|
|
● |
increases
or reductions of our authorized share capital; |
|
|
|
|
● |
a
merger; and |
|
|
|
|
● |
the
exercise of our board of directors’ powers by a general meeting, if our board of directors is unable to exercise its powers
and the exercise of any of its powers is required for our proper management. |
The
Companies Law and our amended and restated articles of association require that a notice of any annual general meeting or extraordinary
general meeting be provided to shareholders at least 21 days prior to the meeting and if the agenda of the meeting includes the appointment
or removal of directors, the approval of transactions with office holders or interested or related parties, or an approval of a merger,
notice must be provided at least 35 days prior to the meeting.
Under
the Companies Law and our amended and restated articles of association, shareholders are not permitted to take action via written consent
in lieu of a meeting.
Voting
Rights
Quorum
Requirements
Pursuant
to our amended and restated articles of association, holders of our ordinary shares have one vote for each ordinary share held on all
matters submitted to a vote before the shareholders at a general meeting. The quorum required for our general meetings of shareholders
consists of one holder of at least 33 1/3% of the total outstanding voting rights present in person, by proxy or written ballot. A meeting
adjourned for lack of a quorum is generally adjourned to the same day in the following week at the same time and place or to a later
time or date if so specified in the notice of the meeting. At the reconvened meeting, one holder of at least 33 1/3% of the total outstanding
voting rights present in person, by proxy or written ballot, shall constitute a lawful quorum.
Vote
Requirements
Our
amended and restated articles of association provide that all resolutions of our shareholders require a simple majority vote of the voting
power present and voting at the applicable shareholders meeting, in person or by proxy, unless otherwise required by the Companies Law
or by our amended and restated articles of association. Under the Companies Law, each of (i) the approval of an extraordinary transaction
with a controlling shareholder and (ii) the terms of employment or other engagement of the controlling shareholder of the company or
such controlling shareholder’s relative (even if not extraordinary) requires, the approval of our audit committee, our board of
directors and a special majority, in that order. Under our amended and restated articles of association, the alteration of the rights,
privileges, preferences or obligations of any class of our shares requires a simple majority vote of the class so affected (or such other
percentage of the relevant class that may be set forth in the governing documents relevant to such class), in addition to the ordinary
majority vote of all classes of shares voting together as a single class at a shareholder meeting. An exception to the simple majority
vote requirement is a resolution for the voluntary winding up, or an approval of a scheme of arrangement or reorganization, of the company
pursuant to Section 350 of the Companies Law, which requires the approval of holders of 75% of the voting rights represented at the meeting,
in person, by proxy or by voting deed and voting on the resolution.
Access
to Corporate Records
Under
the Companies Law, shareholders are provided access to: minutes of our general meetings; our shareholders register and principal shareholders
register, articles of association and financial statements; and any document that we are required by law to file publicly with IROC or
the Israel Securities Authority. In addition, shareholders may request to be provided with any document related to an action or transaction
requiring shareholder approval under the related party transaction provisions of the Companies Law. We may deny this request if we believe
it has not been made in good faith or if such denial is necessary to protect our interest or protect a trade secret or patent.
Modification
of Class Rights
Under
the Companies Law and our amended and restated articles of association, the rights attached to any class of share, such as voting, liquidation
and dividend rights, may be amended by adoption of a resolution by the holders of a majority of the shares of that class present at a
separate class meeting, or otherwise in accordance with the rights attached to such class of shares, as set forth in our amended and
restated articles of association.
Acquisitions
under Israeli Law
Full
Tender Offer
A
person wishing to acquire shares of an Israeli public company and who would as a result hold over 90% of the target company’s issued
and outstanding share capital is required by the Companies Law to make a tender offer to all of the company’s shareholders for
the purchase of all of the issued and outstanding shares of the company. A person wishing to acquire shares of a public Israeli company
and who would as a result hold over 90% of the issued and outstanding share capital of a certain class of shares is required to make
a tender offer to all of the shareholders who hold shares of the relevant class for the purchase of all of the issued and outstanding
shares of that class. If the shareholders who do not accept the offer hold less than 5% of the issued and outstanding share capital of
the company or of the applicable class, and more than half of the shareholders who do not have a personal interest in the offer accept
the offer, all of the shares that the acquirer offered to purchase will be transferred to the acquirer by operation of law. However,
a tender offer will also be accepted if the shareholders who do not accept the offer hold less than 2% of the issued and outstanding
share capital of the company or of the applicable class of shares.
Upon
a successful completion of such a full tender offer, any shareholder that was an offeree in such tender offer, whether such shareholder
accepted the tender offer or not, may, within six months from the date of acceptance of the tender offer, petition an Israeli court to
determine whether the tender offer was for less than fair value and that the fair value should be paid as determined by the court. However,
under certain conditions, the offeror may include in the terms of the tender offer that an offeree who accepted the offer will not be
entitled to petition the Israeli court as described above.
If
(a) the shareholders who did not respond or accept the tender offer hold at least 5% of the issued and outstanding share capital of the
company or of the applicable class or the shareholders who accept the offer constitute less than a majority of the offerees that do not
have a personal interest in the acceptance of the tender offer, or (b) the shareholders who did not accept the tender offer hold 2% or
more of the issued and outstanding share capital of the company (or of the applicable class), the acquirer may not acquire shares of
the company that will increase its holdings to more than 90% of the company’s issued and outstanding share capital or of the applicable
class from shareholders who accepted the tender offer.
Special
Tender Offer
The
Companies Law provides that an acquisition of shares of an Israeli public company must be made by means of a special tender offer if
as a result of the acquisition the purchaser would become a holder of 25% or more of the voting rights in the company. This requirement
does not apply if there is already another holder of at least 25% of the voting rights in the company. Similarly, the Companies Law provides
that an acquisition of shares in a public company must be made by means of a special tender offer if, as a result of the acquisition,
the purchaser would become a holder of more than 45% of the voting rights in the company, provided that there is no other shareholder
of the company who holds more than 45% of the voting rights in the company, subject to certain exceptions.
The
Companies Law provides that an acquisition of shares of an Israeli public company must be made by means of a special tender offer if
as a result of the acquisition the purchaser would become a holder of 25% or more of the voting rights in the company. This requirement
does not apply if there is already another holder of at least 25% of the voting rights in the company. Similarly, the Companies Law provides
that an acquisition of shares in a public company must be made by means of a special tender offer if, as a result of the acquisition,
the purchaser would become a holder of more than 45% of the voting rights in the company, provided that there is no other shareholder
of the company who holds more than 45% of the voting rights in the company, subject to certain exceptions.
A
special tender offer must be extended to all shareholders of a company but the offeror is not required to purchase shares representing
more than 5% of the voting power attached to the company’s outstanding shares, regardless of how many shares are tendered by shareholders.
A special tender offer may be consummated only if (i) outstanding shares representing at least 5% of the voting power of the company
will be acquired by the offeror and (ii) the number of shares tendered in the offer exceeds the number of shares whose holders objected
to the offer (excluding the purchaser, controlling shareholders, holders of 25% or more of the voting rights in the company or any person
having a personal interest in the acceptance of the tender offer). If a special tender offer is accepted, then the purchaser or any person
or entity controlling it or under common control with the purchaser or such controlling person or entity may not make a subsequent tender
offer for the purchase of shares of the target company and may not enter into a merger with the target company for a period of one year
from the date of the offer, unless the purchaser or such person or entity undertook to effect such an offer or merger in the initial
special tender offer.
Merger
The
Companies Law permits merger transactions if approved by each party’s board of directors and, unless certain requirements described
under the Companies Law are met, by a majority vote of each party’s shareholders, and, in the case of the target company, a majority
vote of each class of its shares, voted on the proposed merger at a shareholders meeting.
For
purposes of the shareholder vote, unless a court rules otherwise, the merger will not be deemed approved if a majority of the votes of
shares represented at the shareholders meeting that are held by parties other than the other party to the merger, or by any person (or
group of persons acting in concert) who holds (or hold, as the case may be) 25% or more of the voting rights or the right to appoint
25% or more of the directors of the other party, vote against the merger. If, however, the merger involves a merger with a company’s
own controlling shareholder or if the controlling shareholder has a personal interest in the merger, then the merger is instead subject
to the same Special Majority approval that governs all extraordinary transactions with controlling shareholders. A “Special Majority”
approval constitutes shareholder approval by a majority vote of the shares present and voting at a meeting of shareholders called for
such purpose, provided that either: (a) such majority includes at least a majority of the shares held by all shareholders who are not
controlling shareholders and do not have a personal interest in such compensation arrangement; or (b) the total number of shares of non-controlling
shareholders and shareholders who do not have a personal interest in the compensation arrangement and who vote against the arrangement
does not exceed 2% of the company’s aggregate voting rights.
If
the transaction would have been approved by the shareholders of a merging company but for the separate approval of each class or the
exclusion of the votes of certain shareholders as provided above, a court may still approve the merger upon the request of holders of
at least 25% of the voting rights of a company, if the court holds that the merger is fair and reasonable, taking into account the value
of the parties to the merger and the consideration offered to the shareholders of the target company.
Upon
the request of a creditor of either party to the proposed merger, the court may delay or prevent the merger if it concludes that there
exists a reasonable concern that, as a result of the merger, the surviving company will be unable to satisfy the obligations of the merging
entities, and may further give instructions to secure the rights of creditors.
In
addition, a merger may not be consummated unless at least 50 days have passed from the date on which a proposal for approval of the merger
was filed by each party with IROC and at least 30 days have passed from the date on which the merger was approved by the shareholders
of each party.
Anti-Takeover
Measures under Israeli Law
The
Companies Law allow us to create and issue shares having rights different from those attached to our ordinary shares, including shares
providing certain preferred rights with respect to voting, distributions or other matters and shares having preemptive rights. No preferred
shares are currently authorized under our amended and restated articles of association. In the future, if we do authorize, create and
issue a specific class of preferred shares, such class of shares, depending on the specific rights that may be attached to it, may have
the ability to frustrate or prevent a takeover or otherwise prevent our shareholders from realizing a potential premium over the market
value of their ordinary shares. The authorization and designation of a class of preferred shares will require an amendment to our amended
and restated articles of association, which requires the prior approval of the holders of a majority of the voting power attaching to
our issued and outstanding shares at a general meeting. The convening of the meeting, the shareholders entitled to participate and the
majority vote required to be obtained at such a meeting will be subject to the requirements set forth in the Companies Law as described
above in “—Voting Rights.”
Borrowing
Powers
Pursuant
to the Companies Law and our amended and restated articles of association, our board of directors may exercise all powers and take all
actions that are not required under law or under our amended and restated articles of association to be exercised or taken by our shareholders,
including the power to borrow money for company purposes.
Changes
in Capital
Our
amended and restated articles of association enable us to increase or reduce our share capital. Any such changes are subject to the provisions
of the Companies Law and must be approved by a resolution duly passed by our shareholders at a general meeting by voting on such change
in the capital. In addition, transactions that have the effect of reducing capital, such as the declaration and payment of dividends
in the absence of sufficient retained earnings or profits, require the approval of both our board of directors and an Israeli court.
Warrants
As
of the date hereof, warrants to purchase 113,569 ordinary shares were issued and outstanding at a weighted average exercise
price of $94.91 per ordinary share. 94,998 warrants expire on June 30, 2032, and 18,571 pre-funded warrants have
no expiration date.
Transfer
Agent and Registrar
Our
transfer agent in the United States is Equiniti Trust Company.
Listing
Our
ordinary shares are listed on The Nasdaq Capital Market under the symbol “NTBL.”
Description
of Warrants
We
may issue warrants, options or rights to purchase our equity securities or other rights, including rights to receive payment in cash
or securities based on the value, rate or price of one or more specified securities or indices, or any combination of the foregoing.
Warrants may be issued independently or together with any other securities and may be attached to, or separate from, such securities.
Each series of warrants will be issued under a separate warrant agreement to be entered into between us and a warrant agent. The terms
of any warrants to be issued and a description of the material provisions of the applicable warrant agreement will be set forth in the
applicable prospectus supplement.
The
applicable prospectus supplement will describe the following terms of any warrants in respect of which the prospectus is being delivered:
|
● |
the
title of such warrants; |
|
|
|
|
● |
the
aggregate number of such warrants; |
|
|
|
|
● |
the
price or prices at which such warrants will be issued; |
|
|
|
|
● |
the
currency or currencies, in which the price of such warrants will be payable; |
|
|
|
|
● |
the
securities or other rights, including rights to receive payment in cash or securities based on the value, rate or price of one or
more specified commodities, currencies, securities or indices, or any combination of the foregoing, purchasable upon exercise of
such warrants; |
|
|
|
|
● |
the
date on which the right to exercise such warrants shall commence and the date on which such right shall expire; |
|
|
|
|
● |
if
applicable, the minimum or maximum amount of such warrants which may be exercised at any one time; |
|
|
|
|
● |
if
applicable, the designation and terms of the securities with which such warrants are issued and the number of such warrants issued
with each such security; |
|
|
|
|
● |
if
applicable, the date on and after which such warrants and the related securities will be separately transferable; |
|
|
|
|
● |
information
with respect to book-entry procedures, if any; |
|
|
|
|
● |
any
material Israeli and U.S. federal income tax consequences; |
|
|
|
|
● |
the
anti-dilution provisions of the warrants; and |
|
|
|
|
● |
any
other terms of such warrants, including terms, procedures and limitations relating to the exchange and exercise of such warrants. |
Description
of Units
We
may issue units comprised of ordinary shares and warrants in any combination. We may issue units in such amounts and in as many distinct
series as we wish. This section outlines certain provisions of the units that we may issue. If we issue units, they will be issued under
one or more unit agreements to be entered into between us and a bank or other financial institution, as unit agent. The information described
in this section may not be complete in all respects and is qualified entirely by reference to the unit agreement with respect to the
units of any particular series. The specific terms of any series of units offered will be described in the applicable prospectus supplement.
If so described in a particular supplement, the specific terms of any series of units may differ from the general description of terms
presented below. We urge you to read any prospectus supplement related to any series of units we may offer, as well as the complete unit
agreement and unit certificate that contain the terms of the units. If we issue units, forms of unit agreements and unit certificates
relating to such units will be incorporated by reference as exhibits to the registration statement, which includes this prospectus.
Each
unit that we may issue will be issued so that the holder of the unit is also the holder of each security included in the unit. Thus,
the holder of a unit will have the rights and obligations of a holder of each included security. The unit agreement under which a unit
is issued may provide that the securities included in the unit may not be held or transferred separately, at any time or at any time
before a specified date. The applicable prospectus supplement may describe:
|
● |
the
designation and terms of the units and of the securities comprising the units, including whether and under what circumstances those
securities may be held or transferred separately; |
|
|
|
|
● |
any
provisions of the governing unit agreement; |
|
|
|
|
● |
the
price or prices at which such units will be issued; |
|
|
|
|
● |
the
applicable Israeli and U.S. federal income tax considerations relating to the units; |
|
|
|
|
● |
any
provisions for the issuance, payment, settlement, transfer or exchange of the units or of the securities comprising the units; and |
|
|
|
|
● |
any
other terms of the units and of the securities comprising the units. |
The
provisions described in this section, as well as those described under “Description of Share Capital” and “Description
of Warrants” will apply to the securities included in each unit, to the extent relevant and as may be updated in any prospectus
supplements.
Issuance
in Series
We
may issue units in such amounts and in as many distinct series as we wish. This section summarizes terms of the units that apply generally
to all series. Most of the financial and other specific terms of your series will be described in the applicable prospectus supplement.
Unit
Agreements
We
will issue the units under one or more unit agreements to be entered into between us and a bank or other financial institution, as unit
agent. We may add, replace or terminate unit agents from time to time. We will identify the unit agreement under which each series of
units will be issued and the unit agent under that agreement in the applicable prospectus supplement.
The
following provisions will generally apply to all unit agreements unless otherwise stated in the applicable prospectus supplement:
Modification
without Consent
We
and the applicable unit agent may amend any unit or unit agreement without the consent of any holder:
| ● | to
cure any ambiguity in any provisions of the governing unit agreement that differ from those
described below; |
| ● | to
correct or supplement any defective or inconsistent provision; or |
| ● | to
make any other change that we believe is necessary or desirable and will not adversely affect
the interests of the affected holders in any material respect. |
We
do not need any approval to make changes that affect only units to be issued after the changes take effect. We may also make changes
that do not adversely affect a particular unit in any material respect, even if they adversely affect other units in a material respect.
In those cases, we do not need to obtain the approval of the holder of the unaffected unit; we need only obtain any required approvals
from the holders of the affected units.
Modification
with Consent
We
may not amend any particular unit or a unit agreement with respect to any particular unit unless we obtain the consent of the holder
of that unit, if the amendment would:
| ● | impair
any right of the holder to exercise or enforce any right under a security included in the
unit if the terms of that security require the consent of the holder to make any changes
that would impair the exercise or enforcement of that right; or |
| ● | reduce
the percentage of outstanding units or any series or class the consent of whose holders is
required to amend that series or class, or the applicable unit agreement with respect to
that series or class, as described below. |
Any
other change to a particular unit agreement and the units issued under that agreement would require the following approval:
| ● | If
the change affects only the units of a particular series issued under that agreement, the
change must be approved by the holders of a majority of the outstanding units of that series;
or |
| ● | If
the change affects the units of more than one series issued under that agreement, it must
be approved by the holders of a majority of all outstanding units of all series affected
by the change, with the units of all the affected series voting together as one class for
this purpose. These provisions regarding changes with majority approval also apply to changes
affecting any securities issued under a unit agreement, as the governing document. |
In
each case, the required approval must be given by written consent.
Mergers
and Similar Transactions Permitted; No Restrictive Covenants or Events of Default
The
unit agreements will not restrict our ability to merge or consolidate with, or sell our assets to, another corporation or other entity
or to engage in any other transactions. If at any time we merge or consolidate with, or sell our assets substantially as an entirety
to, another corporation or other entity, the successor entity will succeed to and assume our obligations under the unit agreements. We
will then be relieved of any further obligation under these agreements.
The
unit agreements will not include any restrictions on our ability to put liens on our assets, nor will they restrict our ability to sell
our assets. The unit agreements also will not provide for any events of default or remedies upon the occurrence of any events of default.
Governing
Law
The
unit agreements and the units will be governed by New York law.
Form,
Exchange and Transfer
We
will issue each unit in global—i.e., book-entry—form only. Units in book-entry form will be represented by a global security
registered in the name of a depositary, which will be the holder of all the units represented by the global security. Those who own beneficial
interests in a unit will do so through participants in the depositary’s system, and the rights of these indirect owners will be
governed solely by the applicable procedures of the depositary and its participants. We will describe book-entry securities, and other
terms regarding the issuance and registration of the units in the applicable prospectus supplement.
Each
unit and all securities comprising the unit will be issued in the same form.
If
we issue any units in registered, non-global form, the following will apply to them.
| ● | The
units will be issued in the denominations stated in the applicable prospectus supplement.
Holders may exchange their units for units of smaller denominations or combined into fewer
units of larger denominations, as long as the total amount is not changed. |
| ● | Holders
may exchange or transfer their units at the office of the unit agent. Holders may also replace
lost, stolen, destroyed or mutilated units at that office. We may appoint another entity
to perform these functions or perform them ourselves. |
| ● | Holders
will not be required to pay a service charge to transfer or exchange their units, but they
may be required to pay for any tax or other governmental charge associated with the transfer
or exchange. The transfer or exchange, and any replacement, will be made only if our transfer
agent is satisfied with the holder’s proof of legal ownership. The transfer agent may
also require an indemnity before replacing any units. |
| ● | If
we have the right to redeem, accelerate or settle any units before their maturity, and we
exercise our right as to less than all those units or other securities, we may block the
exchange or transfer of those units during the period beginning 15 days before the day we
mail the notice of exercise and ending on the day of that mailing, in order to freeze the
list of holders to prepare the mailing. We may also refuse to register transfers of or exchange
any unit selected for early settlement, except that we will continue to permit transfers
and exchanges of the unsettled portion of any unit being partially settled. We may also block
the transfer or exchange of any unit in this manner if the unit includes securities that
are or may be selected for early settlement. |
Only
the depositary will be entitled to transfer or exchange a unit in global form, since it will be the sole holder of the unit.
Payments
and Notices
In
making payments and giving notices with respect to our units, we will follow the procedures as described in the applicable prospectus
supplement.
Plan
of Distribution
We
may sell securities under this prospectus in offerings:
| ● | through
one or more underwriters or dealers; |
| | |
| ● | through
other agents; |
| | |
| ● | directly
to holders of our securities pursuant to subscription rights distributed to holders of our
securities; or |
| | |
| ● | directly
to investors. |
We
may price the securities we sell under this prospectus:
| ● | at
a fixed public offering price or prices, which we may change from time to time; |
| | |
| ● | at
market prices prevailing at the times of sale; |
| | |
| ● | at
prices calculated by a formula based on prevailing market prices; |
| | |
| ● | at
negotiated prices; or |
| | |
| ● | in
a combination of any of the above pricing methods. |
If
we use underwriters for an offering, they will acquire securities for their own account and may resell them from time to time in one
or more transactions at a fixed public offering price or at varying prices determined at the time of sale. The obligations of the underwriters
to purchase the securities will be subject to the conditions set forth in the applicable underwriting agreement. We may offer the securities
to the public through underwriting syndicates represented by managing underwriters or by underwriters without a syndicate. Subject to
certain conditions and except as otherwise set forth in the applicable prospectus supplement, the underwriters will be obligated to purchase
all the securities of the series offered by the prospectus supplement. The public offering price and any discounts or concessions allowed
or re-allowed or paid to dealers may change from time to time. Only underwriters named in a prospectus supplement are underwriters of
the securities offered by that prospectus supplement.
We
may grant to the underwriters options to purchase additional securities to cover over-allotments, if any, at the public offering price
with additional underwriting discounts or commissions. If we grant any over-allotment option, the terms of any over-allotment option
will be set forth in the prospectus supplement relating to those securities.
We
may also sell securities directly or through agents. We will name any agent involved in an offering and we will describe any commissions
we will pay the agent in the prospectus supplement. Unless the prospectus supplement states otherwise, our agents will act on a best-efforts
basis.
We
may authorize agents or underwriters to solicit offers by certain types of institutional investors to purchase securities from us at
the public offering price set forth in the prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery
on a specified date in the future. We will describe the conditions of these contracts and the commissions we must pay for solicitation
of these contracts in the prospectus supplement.
We
may provide agents and underwriters with indemnification against certain civil liabilities, including liabilities under the Securities
Act, or contribution with respect to payments that the agents or underwriters may make with respect to such liabilities. Underwriters
or agents may engage in transactions with us, or perform services for us, in the ordinary course of business. We may also use underwriters
or agents with whom we have a material relationship. We will describe the nature of any such relationship in the prospectus supplement.
An
underwriter may engage in overallotment, stabilizing transactions, short covering transactions and penalty bids in accordance with Regulation
M under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Overallotment involves sales in excess
of the offering size, which create a short position. Stabilizing transactions permit bids to purchase the underlying security so long
as the stabilizing bids do not exceed a specified maximum. Short covering transactions involve purchases of the securities in the open
market after the distribution is completed to cover short positions. Penalty bids permit the underwriter to reclaim a selling concession
from a dealer when the securities originally sold by the dealer are purchased in a covering transaction to cover short positions. These
activities may cause the price of our securities to be higher than it would otherwise be on the open market. The underwriter may discontinue
any of these activities at any time.
All
securities we offer, other than ordinary shares, will be new issues of securities, with no established trading market. Underwriters may
make a market in these securities, but will not be obligated to do so and may discontinue market making at any time without notice. We
cannot guarantee the liquidity of the trading markets for any securities.
Sales
to or through one or more underwriters or agents in at-the-market offerings will be made pursuant to the terms of the applicable underwriting
sales or distribution agreement with the underwriters or agents. Such underwriters or agents may act on an agency basis or on a principal
basis. During the term of any such agreement, our ordinary shares may be sold on a daily basis on any stock exchange, market or trading
facility on which the ordinary shares are traded, in privately negotiated transactions or otherwise as agreed with the underwriters or
agents. The agreement will provide that any ordinary shares sold will be sold at negotiated prices or at prices related to the then prevailing
market prices for our ordinary shares. Therefore, exact figures regarding proceeds that will be raised or commissions to be paid cannot
be determined at this time and will be described in a prospectus supplement. Pursuant to the terms of such agreement, we may also agree
to sell, and the relevant underwriters or agents may agree to solicit offers to purchase, blocks of our ordinary shares. The terms of
each such agreement will be described in a prospectus supplement.
We
may loan or pledge securities to a financial institution or other third party that in turn may sell the securities using this prospectus.
Such financial institution or third party may transfer its short position to investors in our securities or in connection with a simultaneous
offering of other securities offered by this prospectus.
The
aggregate net proceeds to us from the sale of ordinary shares will be the purchase price of such ordinary shares less any discounts,
concessions or commissions.
Foreign
Exchange Controls and Other Limitations
There
are currently no Israeli currency control restrictions on remittances of dividends on our ordinary shares, proceeds from the sale of
the ordinary shares or interest or other payments to non-residents of Israel, except for shareholders who are subjects of countries that
are, or have been, in a state of war with Israel.
Taxation
U.S.
federal income tax considerations for U.S. holders
The
applicable prospectus supplement may contain information about any material U.S. federal income tax considerations relating to the securities
covered by such prospectus supplement.
Israeli
taxation
Our
most recent Annual Report on Form 10-K, as updated by other reports and documents we file with the SEC after the date of this prospectus
and that are incorporated by reference herein, provides a discussion of the material Israeli tax consequences that may be relevant to
prospective investors in our ordinary shares. The applicable prospectus supplement may also contain information about any Israeli tax
considerations relating to the securities covered by such prospectus supplement.
Enforceability
of Civil Liabilities and OTHER MATTERS
We
are incorporated under the laws of the State of Israel and maintain our principal executive office in the United States. Service of process
upon our directors and officers, some of whom reside outside of the United States, and the Israeli experts named in this registration
statement, who reside outside of the United States, may be difficult to obtain within the United States.
We
have been informed by our legal counsel in Israel, Meitar Law Offices, that it may be difficult to assert U.S. securities law claims
in original actions instituted in Israel. Israeli courts may refuse to hear a claim based on an alleged violation of U.S. securities
laws reasoning that Israel is not the most appropriate forum to bring such a claim. In addition, even if an Israeli court agrees to hear
a claim, it may determine that Israeli law and not U.S. law is applicable to the claim. If U.S. law is found to be applicable, the content
of applicable U.S. law must be proved as a fact which can be a time-consuming and costly process. Certain matters of procedure will also
be governed by Israeli law.
Subject
to specified time limitations and legal procedures, Israeli courts may enforce a U.S. judgment in a civil matter which, subject to certain
exceptions, is non-appealable, including a judgment based upon the civil liability provisions of the Securities Act and the Exchange
Act and including a monetary or compensatory judgment in a non-civil matter, provided that among other things:
| ● | the
judgment was obtained after due process before a court of competent jurisdiction, according
to the laws of the state in which the judgment was given and the rules of private international
law currently prevailing in Israel; |
| | |
| ● | the
prevailing law of the foreign state in which the judgment was rendered allows for the enforcement
of judgments of Israeli courts; |
| | |
| ● | adequate
service of process has been effected and the defendant has had a reasonable opportunity to
be heard and to present his or her evidence; |
| | |
| ● | the
judgment is not contrary to public policy of Israel, and the enforcement of the civil liabilities
set forth in the judgment is not likely to impair the security or sovereignty of Israel; |
| | |
| ● | the
judgment was not obtained by fraud and do not conflict with any other valid judgments in
the same matter between the same parties; |
| | |
| ● | an
action between the same parties in the same matter is not pending in any Israeli court at
the time the lawsuit is instituted in the foreign court; and |
| | |
| ● | the
judgment is enforceable according to the laws of Israel and according to the law of the foreign
state in which the relief was granted. |
If
a foreign judgment is enforced by an Israeli court, it generally will be payable in Israeli currency, which can then be converted into
non-Israeli currency and transferred out of Israel. The usual practice in an action before an Israeli court to recover an amount in a
non-Israeli currency is for the Israeli court to issue a judgment for the equivalent amount in Israeli currency at the rate of exchange
in force on the date of the judgment, but the judgment debtor may make payment in foreign currency. Pending collection, the amount of
the judgment of an Israeli court stated in Israeli currency ordinarily will be linked to the Israeli consumer price index plus interest
at the annual statutory rate set by Israeli regulations prevailing at the time. Judgment creditors must bear the risk of unfavorable
exchange rates.
For
further information regarding enforceability of civil liabilities against us and other persons, see the discussions in Item 1A of our
Annual Report on Form 10-K for the year ended December 31, 2022, incorporated by reference in this prospectus, under the caption “Risk
Factors—Risks Related to Our Incorporation and Operations in Israel—It may be difficult to enforce a U.S. judgment against
us, our officers and directors and the Israeli experts named in this document in Israel or the United States, or to assert U.S. securities
laws claims in Israel or serve process on our officers and directors and these experts.”
Legal
Matters
The
validity of the securities offered in this prospectus will be passed upon for us by Meitar Law Offices, our Israeli counsel, and by Cravath,
Swaine & Moore LLP, our U.S. counsel. Any underwriters will be advised with respect to other issues relating to any offering by their
own legal counsel.
Experts
The
financial statements of Vascular Biogenics Ltd. as of December 31, 2022 and December 31, 2021 and
for the years then ended incorporated in this prospectus by reference to the Annual Report on Form 10-K for the year ended December
31, 2022, have been so incorporated in reliance on the report of Kesselman & Kesselman, Certified Public Accountants (Isr.), a member
firm of PricewaterhouseCoopers International Ltd., an independent registered public accounting firm, given on the authority of said firm
as experts in auditing and accounting.
The
financial statements of Notable Labs, Inc. as of December 31, 2022 and 2021 and for each of the two years in the period ended December
31, 2022 incorporated by reference in this prospectus have been audited by Deloitte & Touche LLP, an independent auditor,
as stated in their report. Such financial statements are incorporated by reference in reliance upon the report of such firm given
their authority as experts in auditing and accounting.
Where
You Can Find More Information
This
prospectus includes and incorporates by reference additional information and exhibits. We file annual, quarterly and special reports,
proxy statements, registration statements and other information with the SEC. Our SEC filings are also available to the public over the
Internet at the SEC’s website at http://www.sec.gov. You may also access any document we file with the SEC through the Investor
Relations section of our website, which is located at www.notablelabs.com/sec-filings. Information on our website is not incorporated
by reference into this prospectus.
This
prospectus is part of the registration statement and does not contain all of the information included in the registration statement.
Whenever a reference is made in this prospectus to any of our contracts or other documents, the reference may not be complete and, for
a copy of the contract or document, you should refer to the exhibits that are a part of the registration statement.
The
SEC allows us to “incorporate by reference” into this prospectus the information we file with it, which means that we can
disclose important information to you by referring you to those documents. Information incorporated by reference is part of this prospectus.
We incorporate by reference the documents listed below and amendments to them. These documents and their amendments were previously filed
with the SEC.
This
prospectus will be deemed to incorporate by reference the following documents previously filed by us with the SEC (but not portions of
such reports that are “furnished” under items 2.02 or 7.01 of any Form 8-K which are not deemed filed under the Exchange
Act):
| ● | our
Annual Report on Form 10-K for the year ended December 31, 2022; |
| ● | our
Quarterly Reports on Form 10-Q for the quarters ended March 31, 2023 and June 30, 2023, filed
with the SEC on May 15, 2023 and August 14, 2023, respectively; |
| ● | our
Current Reports on Form 8-K filed with the SEC on February
16, 2023, February
23, 2023, March
1, 2023, March
9, 2023, September
1, 2023, September
6, 2023, September
18, 2023, October
2, 2023, October
10, 2023, October
12, 2023 and October 16, 2023; and |
| ● | the
following sections from the Registration Statement on Form
S-4 filed on May 11, 2023, as amended: “Risk Factors,” “Management
Prior to and Following the Merger—Executive Officers and Directors Following the Merger,”
“Unaudited Pro Forma Condensed Combined Financial Information,” “Notes
to the Unaudited Pro Forma Condensed Combined Financial Information,” “Notable
Management’s Discussion and Analysis of Financial Condition and Results of Operations,”
“VBL Business,” “Notable Business,” “Principal Shareholders
of Combined Organization,” and the audited financial statements of
Notable Labs, Inc. as of and for the years ended December 31, 2022 and December 31, 2021
and the unaudited interim financial statements of Notable Labs, Inc. as of June 30, 2023
and for the three and six months ended June 30, 2023 and June 30, 2022. |
All
documents we file with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, except as to any portion of any report
or documents that is not deemed filed under such provisions, on or after the date of this prospectus until the earlier of the date on
which all of the securities registered hereunder have been sold or the registration statement of which this prospectus is a part has
been withdrawn, shall be deemed incorporated by reference in this prospectus and to be a part of this prospectus from the date of filing
of those documents.
You
may request a copy of any or all of the documents incorporated by reference but not delivered with this prospectus, at no cost, by writing
or telephoning us at the following address and number: Notable Labs, Ltd., 320 Hatch Drive, Foster City, CA 94404, (415) 851-2410. We
will provide to each person, including any beneficial owner, to whom this prospectus is delivered, a copy of these filings, at no cost,
upon written or oral request to us at: Notable Labs, Ltd., 320 Hatch Drive, Foster City, CA 94404, Attn: Scott McPherson, telephone number:
(415) 851-2410. We will not, however, send exhibits to those documents, unless the exhibits are specifically incorporated by reference
in those documents.
Up
to $100,000,000
Ordinary
Shares
Warrants
Units
PROSPECTUS
PART
II
Information
Not Required In Prospectus
Item
14. Other Expenses of Issuance and Distribution.
The
following is a statement of estimated expenses in connection with the issuance and distribution of the securities being registered, other
than underwriting discounts and commissions.
SEC registration fee | |
$ | 14,760 | |
Nasdaq listing fee | |
| * | |
FINRA filing fee | |
| * | |
Transfer agent and registrar and depositary fees | |
| * | |
Printing expenses | |
| * | |
Legal fees and expenses | |
| * | |
Accounting fees and expenses | |
| * | |
Miscellaneous | |
| * | |
| |
$ | * | |
* |
Estimated expenses not presently known. |
Item
15. Indemnification of Directors and Officers.
Under
the Israeli Companies Law 1999 (the “Companies Law”), a company may not exculpate an office holder from liability for a breach
of the duty of loyalty. An Israeli company may exculpate an office holder in advance from liability to the company, in whole or in part,
for damages caused to the company as a result of a breach of duty of care, but only if a provision authorizing such exculpation is included
in the company’s articles of association. Our amended and restated articles of association include such a provision. The company
may not exculpate in advance a director from liability arising out of a prohibited dividend or distribution to shareholders.
Under
the Companies Law, a company may indemnify an office holder for the following liabilities, payments and expenses incurred for acts performed
by him or her as an office holder, either pursuant to an undertaking given by the company in advance of the act or following the act,
provided its articles of association authorize such indemnification:
| ● | a
monetary liability imposed on him or her in favor of another person pursuant to a judgment,
including a settlement or arbitrator’s award approved by a court. However, if an undertaking
to indemnify an office holder with respect to such liability is provided in advance, then
such an undertaking must be limited to events which, in the opinion of the board of directors,
can be foreseen based on the company’s activities when the undertaking to indemnify
is given, and to an amount, or according to criteria, determined by the board of directors
as reasonable under the circumstances. Such undertaking shall detail the foreseen events
and amount or criteria mentioned above; |
| ● | reasonable
litigation expenses, including reasonable attorneys’ fees, incurred by the office holder
(1) as a result of an investigation or proceeding instituted against him or her by an authority
authorized to conduct such investigation or proceeding, provided that (i) no indictment was
filed against such office holder as a result of such investigation or proceeding; and (ii)
no financial liability was imposed upon him or her as a substitute for the criminal proceeding
as a result of such investigation or proceeding or, if such financial liability was imposed,
it was imposed with respect to an offense that does not require proof of criminal intent
(mens rea); and (2) in connection with a monetary sanction; and |
| ● | reasonable
litigation expenses, including attorneys’ fees, incurred by the office holder or imposed
by a court in proceedings instituted against him or her by the company, on its behalf, or
by a third party, or in connection with criminal proceedings in which the office holder was
acquitted, or as a result of a conviction for an offense that does not require proof of criminal
intent (mens rea). |
In
addition, under the Companies Law, a company may insure an office holder against the following liabilities incurred for acts performed
by him or her as an office holder, if and to the extent provided in the company’s articles of association:
| ● | a
breach of a duty of loyalty to the company, provided that the office holder acted in good
faith and had a reasonable basis to believe that the act would not harm the company; |
| ● | a
breach of duty of care to the company or to a third party, to the extent such a breach arises
out of the negligent conduct of the office holder; |
| ● | an
act or omission committed with intent to derive illegal personal benefit; and |
| ● | a
monetary liability imposed on the office holder in favor of a third party. |
Under
the Companies Law, a company may not indemnify, exculpate or insure an office holder against any of the following:
| ● | a
breach of the duty of loyalty, except for indemnification and insurance for a breach of the
duty of loyalty to the company to the extent that the office holder acted in good faith and
had a reasonable basis to believe that the act would not harm the company; |
| ● | a
breach of the duty of care committed intentionally or recklessly, excluding a breach arising
out of the negligent conduct of the office holder; |
| ● | an
act or omission committed with intent to derive illegal personal benefit; or |
| ● | a
fine or penalty levied against the office holder. |
Under
the Companies Law, exculpation, indemnification and insurance of office holders in a public company must be approved by the compensation
committee and the board of directors and, with respect to certain office holders or under certain circumstances, also by the shareholders.
Our
amended and restated articles of association permit us to exculpate, indemnify and insure our office holders to the fullest extent permitted
under the Companies Law.
We
have entered into indemnification and exculpation agreements with each of our current office holders exculpating them from a breach of
their duty of care to us to the fullest extent permitted by the Companies Law and undertaking to indemnify them to the fullest extent
permitted by the Companies Law.
We
are not aware of any pending or threatened litigation or proceeding involving any of our office holders as to which indemnification is
being sought, nor are we aware of any pending or threatened litigation that may result in claims for indemnification by any office holder.
Item
16. Exhibits.
* | To
be filed by amendment or pursuant to a report to be filed pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934, if applicable, and incorporated herein by reference. |
Item
17. Undertakings.
| (a) | The
undersigned Registrant hereby undertakes: |
| (1) | To
file, during any period in which offers or sales are being made, a post-effective amendment
to this registration statement: |
| (i) | To
include any prospectus required by section 10(a)(3) of the Securities Act of 1933; |
| (ii) | To
reflect in the prospectus any facts or events arising after the effective date of the registration
statement (or the most recent post-effective amendment thereof) which, individually or in
the aggregate, represent a fundamental change in the information set forth in the registration
statement. Notwithstanding the foregoing, any increase or decrease in volume of securities
offered (if the total dollar value of securities offered would not exceed that which was
registered) and any deviation from the low or high end of the estimated maximum offering
range may be reflected in the form of prospectus filed with the Securities and Exchange Commission
pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no
more than a 20% change in the maximum aggregate offering price set forth in the “Calculation
of Filing Fees Tables” or “Calculation of Registration Fee” table, as applicable,
in the effective registration statement; and |
| (iii) | To
include any material information with respect to the plan of distribution not previously
disclosed in the registration statement or any material change to such information in the
registration statement; |
provided,
however, that paragraphs (i), (ii) and (iii) above do not apply if the information required to be included in a post-effective amendment
by those paragraphs is contained in reports filed with or furnished to the Securities and Exchange Commission by the Registrant pursuant
to section 13 or section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the registration statement,
or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement.
| (2) | That,
for the purpose of determining any liability under the Securities Act of 1933, each such
post-effective amendment shall be deemed to be a new registration statement relating to the
securities offered therein, and the offering of such securities at that time shall be deemed
to be the initial bona fide offering thereof. |
| (3) | To
remove from registration by means of a post-effective amendment any of the securities being
registered which remain unsold at the termination of the offering. |
| (4) | That,
for the purpose of determining liability under the Securities Act of 1933 to any purchaser: |
| (i) | If
the Registrant is relying on Rule 430B: |
| A. | Each
prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part
of the registration statement as of the date the filed prospectus was deemed part of and
included in the registration statement; and |
| B. | Each
prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of
a registration statement in reliance on Rule 430B relating to an offering made pursuant to
Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing the information required by
section 10(a) of the Securities Act of 1933 shall be deemed to be part of and included in
the registration statement as of the earlier of the date such form of prospectus is first
used after effectiveness or the date of the first contract of sale of securities in the offering
described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer
and any person that is at that date an underwriter, such date shall be deemed to be a new
effective date of the registration statement relating to the securities in the registration
statement to which that prospectus relates, and the offering of such securities at that time
shall be deemed to be the initial bona fide offering thereof. Provided, however, that
no statement made in a registration statement or prospectus that is part of the registration
statement or made in a document incorporated or deemed incorporated by reference into the
registration statement or prospectus that is part of the registration statement will, as
to a purchaser with a time of contract of sale prior to such effective date, supersede or
modify any statement that was made in the registration statement or prospectus that was part
of the registration statement or made in any such document immediately prior to such effective
date. |
| (ii) | If
the registrant is subject to Rule 430C, each prospectus filed pursuant to Rule 424(b) as
part of a registration statement relating to an offering, other than registration statements
relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be
deemed to be part of and included in the registration statement as of the date it is first
used after effectiveness. Provided, however, that no statement made in a registration statement
or prospectus that is part of the registration statement or made in a document incorporated
or deemed incorporated by reference into the registration statement or prospectus that is
part of the registration statement will, as to a purchaser with a time of contract of sale
prior to such first use, supersede or modify any statement that was made in the registration
statement or prospectus that was part of the registration statement or made in any such document
immediately prior to such date of first use. |
| (5) | That,
for the purpose of determining liability of the registrant under the Securities Act of 1933
to any purchaser in the initial distribution of the securities: |
The
undersigned Registrant undertakes that in a primary offering of securities of the undersigned Registrant pursuant to this registration
statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold
to such purchaser by means of any of the following communications, the undersigned Registrant will be a seller to the purchaser and will
be considered to offer or sell such securities to such purchaser:
| (i) | Any
preliminary prospectus or prospectus of the undersigned Registrant relating to the offering
required to be filed pursuant to Rule 424; |
| (ii) | Any
free writing prospectus relating to the offering prepared by or on behalf of the undersigned
Registrant or used or referred to by the undersigned Registrant; |
| (iii) | The
portion of any other free writing prospectus relating to the offering containing material
information about the undersigned Registrant or its securities provided by or on behalf of
the undersigned Registrant; and |
| (iv) | Any
other communication that is an offer in the offering made by the undersigned Registrant to
the purchaser. |
| (6) | That,
for the purposes of determining any liability under the Securities Act of 1933, each filing
of the Registrant’s annual report pursuant to section 13(a) or section 15(d) of the
Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit
plan’s annual report pursuant to section 15(d) of the Securities Exchange Act of 1934)
that is incorporated by reference in the registration statement shall be deemed to be a new
registration statement relating to the securities offered therein, and the offering of such
securities at that time shall be deemed to be the initial bona fide offering thereof. |
Insofar
as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons
of the Registrant pursuant to any charter provision, by law or otherwise, the Registrant has been advised that in the opinion of the
Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act of 1933 and is, therefore,
unenforceable. In the event that a claim for indemnification against such liabilities (other than payment by the Registrant of expenses
incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding)
is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will,
unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction
the question whether such indemnification by it is against public policy as expressed in the Securities Act of 1933 and will be governed
by the final adjudication of such issue.
| (7) | That,
for purposes of determining any liability under the Securities Act of 1933, the information
omitted from the form of prospectus filed as part of this Registration Statement in reliance
upon Rule 430A and contained in a form of prospectus filed by the Registrant pursuant to
Rule 424(b)(1) or (4) or 497(h) under the Securities Act of 1933 shall be deemed to be part
of this Registration Statement as of the time it was declared effective. |
| (8) | That,
for the purpose of determining any liability under the Securities Act of 1933, each post-effective
amendment that contains a form of prospectus shall be deemed to be a new registration statement
relating to the securities offered therein, and the offering of such securities at that time
shall be deemed to be the initial bona fide offering thereof. |
SIGNATURES
Pursuant
to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all
of the requirements for filing on Form S-3 and has duly caused this Registration Statement to be signed on its behalf by the undersigned,
thereunto duly authorized in Foster City, California, on October 17, 2023.
|
Notable Labs, Ltd. |
|
|
|
|
By: |
/s/
Thomas Bock |
|
|
Thomas
Bock |
|
|
President
and Chief Executive Officer |
POWER
OF ATTORNEY
KNOW
ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Thomas Bock and Scott
A. McPherson, and each of them, his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution,
for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments, including post-effective
amendments, to this Registration Statement, and any registration statement relating to the offering covered by this Registration Statement
and filed pursuant to Rule 462(b) under the Securities Act of 1933, and to file the same, with exhibits thereto and other documents in
connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them,
full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully for all intents
and purposes as he or she might or could do in person, hereby ratifying and confirming all that each of said attorneys in fact and agents
or their substitute or substitutes may lawfully do or cause to be done by virtue hereof.
Pursuant
to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities
and on the dates indicated.
Name |
|
Title |
|
Date |
|
|
|
|
|
/s/
Thomas Bock
|
|
President
and Chief Executive Officer |
|
October
17, 2023 |
Thomas
Bock |
|
(Principal Executive Officer) and Director |
|
|
|
|
|
|
|
/s/
Scott A. McPherson
|
|
Chief
Financial Officer (Principal Financial |
|
October
17, 2023 |
Scott A. McPherson |
|
Officer and Principal Accounting Officer) |
|
|
|
|
|
|
|
/s/
Peter Feinberg
|
|
Director |
|
October
17, 2023 |
Peter Feinberg |
|
|
|
|
|
|
|
|
|
/s/
Michele Galen
|
|
Director |
|
October
17, 2023 |
Michele Galen |
|
|
|
|
|
|
|
|
|
/s/
Tuomo Pätsi
|
|
Director |
|
October
17, 2023 |
Tuomo Pätsi |
|
|
|
|
|
|
|
|
|
/s/
Michael Rice
|
|
Director |
|
October
17, 2023 |
Michael Rice |
|
|
|
|
|
|
|
|
|
/s/
Thomas I. H. Dubin
|
|
Director |
|
October
17, 2023 |
Thomas I. H. Dubin |
|
|
|
|
|
|
|
|
|
/s/
Thomas Graney
|
|
Director |
|
October
17, 2023 |
Thomas
Graney |
|
|
|
|
Exhibit 3.1
AMENDED AND RESTATED
ARTICLES OF ASSOCIATION
OF
VASCULAR BIOGENICS LTD.
A
COMPANY LIMITED BY SHARES
UNDER THE COMPANIES LAW, 5759 - 1999
INTERPRETATION
|
1.1. | In
these Articles, unless the context requires another meaning the words in the first column
of the following table shall have the meanings set opposite them in the second column: |
“
Alternate Nominee ” |
as
defined in Article 77.1; |
|
|
“
Articles ” |
these
Articles of Association, as amended from time to time by a Resolution (as defined below); |
|
|
“
Auditors ” |
the
auditors of the Company; |
|
|
“
Board of Directors ” |
all
of the directors of the Company holding office pursuant to these Articles, including alternates, substitutes or proxies; |
|
|
“
Chief Executive Officer ” |
chief
executive officer of the Company; |
|
|
“
Chairman of the Board of Directors” |
as
defined in Article 81; |
|
|
“
Companies Law ” |
the
Israeli Companies Law, 5759-1999, as amended from time to time, including the regulations promulgated thereunder, or any other law
which may come in its stead, including all amendments made thereto; |
|
|
“
Company ” |
Vascular
Biogenics Ltd. or וסקולר ביוג’ניקס בע”מ
|
|
|
“
Committee of Directors ” |
as
defined in Article 93; |
|
|
“
Compensation Committee ” |
as
defined in the Companies Law; |
|
|
“
Deed of Transfer ” |
as
defined in Article 44; |
|
|
“
Derivative Transaction ” |
as
defined in Article 56; |
|
|
“
Effective Time ” |
the
closing of the initial underwritten public offering of the Company’s Ordinary Shares, at which time these Articles shall first
become effective; |
“
Director(s) ” |
a
member or members of the Board of Directors elected to hold office as director(s); |
|
|
“
External Directors ” |
as
defined in the Companies Law; |
|
|
“
General Meetings ” |
all
annual and extraordinary meetings of the Shareholders; |
|
|
“
Incapacitated Person ” |
as
defined under the Israeli Legal Capacity and Guardianship Law, 5722-1962, as amended from time to time, including a minor who has
not yet attained the age of 18 years, a person unsound of mind and a bankrupt in respect of whom no rehabilitation has been granted; |
|
|
“
NIS ” |
New
Israeli Shekels; |
|
|
“
Nominees ” |
as
defined in Article 77.1; |
|
|
“
Ordinary Shares ” |
as
defined in Article 6; |
|
|
“
Office ” |
the
registered office of the Company at that time; |
|
|
“
Office Holder ” |
as
defined in the Companies Law; |
|
|
“
Person ” |
includes
an individual, corporation, company, cooperative society, partnership, trust of any kind or any other body of persons, whether incorporated
or otherwise; |
|
|
“
Proposal Request ” |
as
defined in Article 56; |
|
|
“
Proposing Shareholder ” |
as
defined in Article 56; |
|
|
“
Register ” |
the
Register of Shareholders administered in accordance with the Companies Law; |
|
|
“
Resolution ” |
a
resolution of Shareholders. Except as required under the Companies Law or these Articles, any Resolution shall be adopted by a majority
of the voting power present and voting at the applicable General Meeting, in person or by proxy; |
|
|
“
Rights ” |
as
defined in Article 113.1; |
|
|
“
Shareholder(s) ” |
shall
mean the shareholder(s) of the Company, at any given time; |
|
|
“
Special Fund ” |
as
defined in Article 113.1; |
|
|
“
Transferor ” |
as
defined in Article 44; |
|
|
“
Transferee ” |
as
defined in Article 44; |
|
|
“
U.S. Rules ” |
the
applicable rules of the NASDAQ Stock Market and the U.S. securities rules and regulations, as amended from time to time; and |
|
|
“
writing ” |
handwriting,
typewriting, photography, telex, email or any other legible form of writing. |
| 1.2. | Subject
to the provisions of this Article 0, in these Articles, unless the context necessitates another
meaning, terms and expressions which have been defined in the Companies Law shall have the
meanings ascribed to them therein. |
| 1.3. | Words
in the singular shall also include the plural, and vice versa. Words in the masculine shall
include the feminine and vice versa, and words which refer to persons shall also include
corporations, and vice versa. |
| 1.4. | The
captions to articles in these Articles are intended for the convenience of the reader only,
and no use shall be made thereof in the interpretation of these Articles. |
LIMITED LIABILITY
2. | The
Company is a limited liability company and therefore each shareholder’s obligations
for the Company’s obligations shall be limited to the payment of the nominal value
of the shares held by such shareholder, subject to the provisions of the Companies Law. |
THE
COMPANY’S OBJECTIVES
3. | The
principal object for which the Company was founded is to engage in any business, commercial,
industry or other activity of any kind which is not legally prohibited or restricted by law. |
THE BUSINESS
4. | Any
branch or type of business that the Company is authorized to engage in, either expressly
or implied, may be commenced or engaged in by the Board of Directors at all or any time as
it deems fit. The Board of Directors shall be entitled to cease the conduct of any such branch
or type of business, whether or not the actual conduct thereof has commenced at its own discretion. |
REGISTERED OFFICE
5. | The
registered office shall be at such place as is decided from time to time by the Board of
Directors. |
SHARE CAPITAL
6. | The
share capital of the Company shall consist of NIS 700,000 divided into 70,000,000 Ordinary
Shares, of a nominal value of NIS 0.01 each (the “ Ordinary Shares “). |
RIGHTS
ATTACHING TO THE ORDINARY SHARES
| 7.1. | The
Ordinary Shares in respect of which all calls have been fully paid shall confer on the holders
thereof the right to attend and to vote at General Meetings of the Company, both ordinary
as well as extraordinary meetings. |
| 7.2. | The
Ordinary Shares shall confer on a holder thereof the right to receive a dividend, to participate
in a distribution of bonus shares and to participate in the distribution of the assets of
the Company upon its winding-up, pro rata to the nominal amount paid up on the shares or
credited as paid up in respect thereof, and without reference to any premium which may have
been paid in respect thereof. |
MODIFICATION
OF CLASS RIGHTS
| 8.1. | Subject
to applicable law, if at any time the share capital of the Company is divided into different
classes of shares and unless the terms of issue of such class of shares otherwise stipulate,
the rights attaching to any class of shares (including rights prescribed in the terms of
issue of the shares) may be altered, modified or canceled, by a Resolution passed at a separate
General Meeting of the Shareholders of that class. |
| 8.2. | The
provisions contained in these Articles with regard to General Meetings shall apply, mutatis
mutandis as the case may be, to every General Meeting of the holders of each such class
of the Company’s shares. |
| 8.3. | Unless
otherwise provided by these Articles, the increase of an authorized class of shares, or the
issuance of additional shares thereof out of the authorized and unissued share capital, shall
not be deemed, for purposes of this Article 8.3, to modify or abrogate the rights attached
to previously issued shares of such class or of any other class. |
UNISSUED
SHARE CAPITAL
9. | The
unissued shares in the capital of the Company shall be under the control of the Board of
Directors, which shall be entitled to allot or otherwise grant the same to such Persons under
such restrictions and conditions as it shall deem fit, whether for consideration or otherwise,
and whether for consideration in cash or for consideration which is not in cash, above their
nominal value or at a discount, all on such conditions, in such manner and at such times
as the Board of Directors shall deem fit, subject to the provisions of the Companies Law.
The Board of Directors shall be entitled, inter alia , to differentiate between Shareholders
with regard to the amounts of calls in respect of the allotment of shares (to the extent
that there are calls) and with regard to the time for payment thereof. The Board of Directors
may also issue options or warrants for the purchase of shares of the Company and prescribe
the manner of the exercise of such options or warrants, including the time and price for
such exercise and any other provision which is relevant to the method for distributing the
issued shares of the Company amongst the purchasers thereof. |
10. | The
Board of Directors shall be entitled to prescribe the times for the issue of shares of the
Company and the conditions therefore and any other matter which may arise in connection with
the issue thereof. |
11. | In
every case of a rights offering the Board of Directors shall be entitled, in its discretion,
to resolve any problems and difficulties arising or that are likely to arise in regard to
fractions of rights, and without prejudice to the generality of the foregoing, the Board
of Directors shall be entitled to specify that no shares shall be allotted in respect of
fractions of rights, or that fractions of rights shall be sold and the (net) proceeds shall
be paid to the persons entitled to the fractions of rights, or, in accordance with a decision
by the Board of Directors, to the benefit of the Company. |
INCREASE
OF AND ALTERATIONS TO CAPITAL
12. | The
Company may, from time to time, by a Resolution, increase its share capital by way of the
creation of new shares, whether or not all the existing shares have been issued up to the
date of the resolution, whether or not it has been decided to issue same, and whether or
not calls have been made on all the issued shares. |
13. |
The
increase of share capital shall be in such amount and divided into shares of such nominal value, and with such restrictions and conditions
and with such rights and privileges as the Resolution dealing with the creation of the shares prescribes, and if no provisions are
contained in the Resolution, then as the Board of Directors shall prescribe. |
14. | Unless
otherwise stated in the Resolution approving the increase of the share capital, the new shares
shall be subject to those provisions in regard to issue, allotment, alteration of rights,
payment of calls, liens, forfeiture, transfer, transmission and other provisions which apply
to the shares of the Company. |
| |
15. | By
Resolution, the Company may, subject to any applicable provisions of the Companies Law: |
| 15.1. | consolidate
its existing share capital, or any part thereof, into shares of a larger denomination than
the existing shares; |
| | |
| 15.2. | sub-divide
its share capital, in whole or in part, into shares of a smaller denomination than the nominal
value of the existing shares and without prejudice to the foregoing, one or more of the shares
so created may be granted any preferred or deferred rights or any special rights with regard
to dividends, participation in assets upon winding- up, voting and so forth, subject to the
provisions of these Articles; |
| | |
| 15.3. | reduce
its share capital; or |
| | |
| 15.4. | cancel
any shares which on the date of passing of the Resolution have not been issued and to reduce
its share capital by the amount of such shares. |
16. | In
the event that the Company shall adopt any of the Resolutions described in Article 15 above,
the Board of Directors shall be entitled to prescribe arrangements necessary in order to
resolve any difficulty arising or that are likely to arise in connection with such Resolutions,
including, in the event of a consolidation, it shall be entitled to (i) allot, in contemplation
of or subsequent to such consolidation or other action, shares or fractional shares sufficient
to preclude or remove fractional share holdings; (ii) redeem, in the case of redeemable shares,
and subject to applicable law, such shares or fractional shares sufficient to preclude or
remove fractional share holdings; (iii) round up, round down or round to the nearest whole
number, any fractional shares resulting from the consolidation or from any other action which
may result in fractional shares; or (iv) cause the transfer of fractional shares by certain
Shareholders to other Shareholders thereof so as to most expediently preclude or remove any
fractional shareholdings, and, cause the transferees of such fractional shares to pay the
transferors thereof the fair value thereof, and the Board of Directors is hereby authorized
to act in connection with such transfer, as agent for the transferors and transferees of
any such fractional shares, with full power of substitution, for the purposes of implementing
the provisions of this Article 16 |
SHARE
CERTIFICATES
17. | To
the extent shares are certificated, share certificates evidencing title to the shares of
the Company shall be issued under the seal or rubber stamp of the Company, and together with
the signatures of two members of the Board of Directors, or one Director together with the
Chief Executive Officer, the Chief Financial Officer, the Secretary of the Company or any
other person designated by the Board of Directors. The Board of Directors shall be entitled
to decide that the signatures be effected in any mechanical or electronic form, provided
that the signature shall be effected under the supervision of the Board of Directors in such
manner as it prescribes. |
| |
18. | Every
Shareholder shall be entitled, free of charge, to one certificate in respect of all the shares
of a single class registered in his name in the Register. |
| |
19. | The
Board of Directors shall not refuse a request by a Shareholder to obtain several certificates
in place of one certificate, unless such request is, in the opinion of the Board of Directors,
unreasonable. Where a Shareholder has sold or transferred some of his shares, he shall be
entitled, free of charge, to receive a certificate in respect of his remaining shares, provided
that the previous certificate is delivered to the Company before the issuance of a new certificate. |
20. | Every
share certificate shall specify the number of the shares in respect of which such certificate
is issued and also the amounts which have been paid up in respect of each share. |
| |
21. | No
Person shall be recognized by the Company as having any right to a share unless such Person
is the registered owner of the shares in the Register. The Company shall not be bound by
and shall not recognize any right or privilege pursuant to the laws of equity, or a fiduciary
relationship or a chose in action, future or partial, in any share, or a right or privilege
to a fraction of a share, or (unless these Articles otherwise direct) any other right in
respect of a share, except the absolute right to the share as a whole, where same is vested
in the owner registered in the Register. |
| |
22. | A
share certificate registered in the names of two or more persons shall be delivered to one
of the joint holders, and the Company shall not be obliged to issue more than one certificate
to all the joint holders of shares and the delivery of such certificate to one of the joint
holders shall be deemed to be delivery to all of them. |
| |
23. | If
a share certificate should be lost, destroyed or defaced, the Board of Directors shall be
entitled to issue a new certificate in its place, provided that the certificate is delivered
to it and destroyed by it, or it is proved to the satisfaction of the Board of Directors
that the certificate was lost or destroyed and security has been received to its satisfaction
in respect of any possible damages and after payment of such amount as the Board of Directors
shall prescribe. |
CALLS
ON SHARES
24. | The
Board of Directors may from time to time, in its discretion, make calls on Shareholders in
respect of amounts which are still unpaid in respect of the shares held by each of the Shareholders
(including premiums), and the terms of issue which do not prescribe that same be paid at
fixed times, and every Shareholder shall be obliged to pay the amount of the call made on
him, at such time and at such place as stipulated by the Board of Directors. |
| |
25. | In
respect of any such call, prior notice of at least fourteen (14) business days shall be given,
stating to whom the amount called is to be paid, the time for payment and the place thereof,
provided that prior to the due date for payment of such call, the Board of Directors may,
by written notice to the Shareholders to which the call was made, cancel the call or extend
the date of payment thereof. |
| |
26. | If
according to the terms of issue of any share, or otherwise, any amount is required to be
paid at a fixed time or in installments at fixed times, whether the payment is made on account
of the share capital in respect of the share or in form of a premium, every such payment
or every such installment shall be paid as if it was a call duly made by the Board of Directors,
in respect of which notice was duly given, and all the provisions contained in these Articles
in regard to calls shall apply to such amount or to such installment. |
| |
27. | Joint
holders of a share shall be jointly and severally liable for the payment of all installments
and calls due in respect of such share. |
| |
28. | In
the event that a call or installment due on account of a share is not paid on or before the
date fixed for payment thereof, the holder of the share, or the Person to whom the share
has been allotted, shall be obliged to pay linkage differentials and interest on the amount
of the call or the installment, at such rate as shall be determined by the Board of Directors,
commencing from the date fixed for the payment thereof and until the date of actual payment.
The Board of Directors may, however, waive the payment of the linkage differentials or the
interest or part thereof. |
| |
29. |
A
Shareholder shall not be entitled (i) to receive a dividend and (ii) to exercise any right as a Shareholder, including but not limited
to, the right to attend and vote at a General Meeting of any type and to transfer the shares to another; unless he has paid all the
calls payable from time to time and which apply to any of his shares, whether he holds same alone or jointly with another, plus linkage
differentials, interest and expenses, if any. |
30. | The
Board of Directors may, if it deems fit, accept payment from a Shareholder wishing to advance
the payment of all moneys which remain unpaid on account of his shares, or part thereof which
are over and above the amounts which have actually been called, and the Board of Directors
shall be entitled to pay such Shareholder linkage differentials and interest in respect of
the amounts paid in advance, or that portion thereof which exceeds the amount called for
the time being on account of the shares in respect of which the advance payment is made,
at such rate as is agreed upon between the Board of Directors and the Shareholder, with this
being in addition to dividends payable (if any) on the paid-up portion of the share in respect
of which the advance payment is made. |
The
Board of Directors may, at any time, repay the amount paid in advance as aforesaid, in whole or in part, in its sole discretion, without
premium or penalty. Nothing in this Article 30 shall derogate from the right of the Board of Directors to make any call for payment before
or after receipt by the Company of any such advance.
FORFEITURE
AND LIEN
31. | If
a Shareholder fails to make payment of any call or other installment on or before the date
fixed for the payment thereof, the Board of Directors may, at any time thereafter and for
as long as the part of the call or installment remains unpaid, serve on such Shareholder
a notice demanding that he make payment thereof, together with the linkage differentials
and interest at such rate as is specified by the Board of Directors and all the expenses
incurred by the Company in consequence of such non-payment. |
| |
32. | The
notice shall specify a further date, which shall be at least fourteen (14) business days
after the date of the delivery of the notice, and a place or places at which such call or
installment is to be paid, together with linkage differentials and interest and expenses
as aforesaid. The notice shall further state that, if the amount is not paid on or before
the date specified, and at the place mentioned in such notice, the shares in respect of which
the call was made, or the installment is due, shall be liable to forfeiture. |
| |
33. | If
the demands contained in such notice are not complied with the Board of Directors may treat
the shares in respect of which the notice referred to in Articles 31 and 32 was given as
forfeited. Such forfeiture shall include all dividends, bonus shares and other benefits which
have been declared in respect of the forfeited shares which have not actually been paid prior
to the forfeiture. |
| |
34. | Any
share so forfeited or waived shall be deemed to be the property of the Company and the Board
of Directors shall be entitled, subject to the provisions of these Articles and the Companies
Law, to sell, re-allot or otherwise dispose thereof, as it deems fit, whether the amount
paid previously in respect of that share is credited, in whole or in part. |
| |
35. | The
Board of Directors may, at any time before any share forfeited as aforesaid is sold or re-
allotted or otherwise dispose of, cancel the forfeiture on such conditions as it deems fit. |
| |
36. | Any
Person whose shares have been forfeited shall cease to be a Shareholder in respect of the
forfeited shares, but shall, nonetheless remain liable for the payment to the Company of
all calls, installments, linkage differentials, interest and expenses due on account of or
in respect of such shares on the date of forfeiture, in respect of the forfeited shares,
together with interest on such amounts reckoned from the date of forfeiture until the date
of payment, at such rate as the Board of Directors shall from time to time specify. However,
such Person’s liability shall cease after the Company has received all the amounts
called in respect of the shares as well as any expenses incurred by the Company relating
to collecting the amounts called. The Board of Directors shall be entitled to collect the
moneys which have been forfeited, or part thereof, as it shall deem fit, but it shall not
be obliged to do so. |
37. | The
provisions of these Articles in regard to forfeiture shall also apply to cases of non- payment
of any amount, which, according to the terms of issue of the share, or which under the conditions
of allotment the due date for payment of which fell on a fixed date, whether this be on account
of the nominal value of the share or in the form of a premium, as if such amount was payable
pursuant to a call duly made and notified. |
| |
38. | The
Company shall have a first and paramount lien over all the shares which have not been fully
paid up and which are registered in the name of any Shareholder (whether individually or
jointly with others) and also over the proceeds of the sale thereof, as security for the
debts and obligations of such Shareholder to the Company and his contractual engagements
with it, either individually or together with others. This right of lien shall apply whether
or not the due date for payment of such debts or the fulfillment or performance of such obligations
has arrived, and no rights in equity shall be created in respect of any share, over which
there is a lien as aforesaid. The aforesaid lien shall apply to all dividends or benefits
which may be declared, from time to time, on such shares, unless the Board of Directors shall
decide otherwise. |
| |
39. | In
order to foreclose on such lien, the Board of Directors may sell the shares under lien at
such time and in such manner as, it shall deem fit, but no share may be sold unless the period
referred to below has elapsed and written notice has been given to the Shareholder, his trustee,
liquidator, receiver, the executors of his estate, or anyone who acquires a right to shares
in consequence of the bankruptcy of a Shareholder, as the case may be, stating that the Company
intends to sell the shares, if he or they should fail to pay the aforesaid debts, or fail
to discharge or fulfill the aforesaid obligations within fourteen (14) business days from
the date of the delivery of the notice. |
| |
40. | The
net proceeds of any such sale of shares, as contemplated by Article 39 above, after deduction
of the expenses of the sale, shall serve for the discharge of the debts of such shareholder
or for performance of such Shareholder’s obligations (including debts, undertakings
and contractual engagements the due date for the payment or performance of which has arrived)
and the surplus, if any, shall be paid to the Shareholder, his trustee, liquidator, receiver,
guardians, the executors of his estate, or to his successors-in-title. |
| |
41. | In
every case of a sale following forfeiture or waiver, or for purposes of executing a lien
by exercising all of the powers conferred above, the Board of Directors shall be entitled
to appoint a person to sign an instrument of transfer of the shares sold, and to arrange
for the registration of the name of the buyer in the Register in respect of the shares sold. |
| |
42. | An
affidavit signed by the Chairman of the Board of Directors that a particular share of the
Company was forfeited, waived or sold by the Company by virtue of a lien, shall serve as
conclusive evidence of the facts contained therein as against any person claiming a right
in the share. The purchaser of a share who relies on such affidavit shall not be obliged
to investigate whether the sale, re-allotment or transfer, or the amount of consideration
and the manner of application of the proceeds of the sale, were lawfully effected, and after
his name has been registered in the Register he shall have a full right of title to the share
and such right shall not be adversely affected by a defect or invalidity which occurred in
the forfeiture, waiver, sale, re-allotment or transfer of the share. |
TRANSFER
AND TRANSMISSION OF SHARES
43. | No
transfer of shares shall be registered unless a proper instrument of transfer is delivered
to the Company or, in the case of shares registered with a transfer agent, delivered to such
transfer agent or to such other place specified for this purpose by the Board of Directors.
Subject to the provisions of these Articles, an instrument of transfer of a share in the
Company shall be signed by the transferor and the transferee. The Board of Directors may
approve other methods of recognizing the transfer of shares in order to facilitate the trading
of the Company’s shares on the Nasdaq Global Market or on any other stock exchange.
The transferor shall be deemed to remain the holder of the share up until the time the name
of the transferee is registered in the Register in respect of the transferred share. |
44. | Insofar
as the circumstances permit, the instrument of transfer of a share shall be substantially
in the form set out below, or in any other form that the Board of Directors may approve (the
“Deed of Transfer “). |
I
, I.D. of (the “ Transferor “), in consideration for an amount of NIS (in words) paid to me by I.D. of
(hereinafter: the “ Transferee “), hereby transfer to the Transferee shares of nominal value NIS each, marked
with the Numbers to (inclusive) of a company known as Vascular Biogenics Ltd., to be held by the Transferee, the acquires of his
rights and his successors-in title, under all the same conditions under which I held same prior to the signing of this instrument,
and I, the Transferee, hereby agree to accept the aforementioned share in accordance with the above mentioned conditions.
In
witness whereof we have hereunto signed this day
of 20 .
|
Transferor ___________________ |
Transferee _______________ |
|
|
|
|
|
|
|
|
Witnesses
to Signature
___________________________ |
|
|
45. | The
Company may close the transfer registers and the Register for such period of time as the
Board of Directors shall deem fit. |
| |
46. | Every
instrument of transfer shall be submitted to the Office or to such other place as the Board
of Directors shall prescribe, for purposes of registration, together with the share certificates
to be transferred, or if no such certificate was issued, together with a letter of allotment
of the shares to be transferred, and/or such other proof as the Board of Directors may demand
in regard to the transferor’s right of title or his right to transfer the shares. The
Board of Directors shall have the right to refuse to recognize an assignment of shares until
the appropriate securities under the circumstances have been provided, as shall be determined
by the Board of Directors in a specific case or from time to time in general. Instruments
of transfer which serve as the basis for transfers that are registered shall remain with
the Company. |
| |
47. | Every
instrument of transfer shall relate to one class of shares only, unless the Board of Directors
shall otherwise agree. |
| |
48. | The
executors of the will or administrator of a deceased Shareholder’s estate (such Shareholder
not being one of a joint owners of a share) or, in the absence of an administrator of the
estate or executor of the will, the persons specified in Article 49 below, shall be entitled
to demand that the Company recognize them as owners of rights in the share. The provisions
of Article 46 above shall apply, mutatis mutandis , also in regard to this Article. |
| |
49. | In
the case of the death of one of the holders of a share registered in the names of two or
more Persons, the Company shall recognize only the surviving owners as Persons having rights
in the share. However, the aforementioned shall not be construed as releasing the estate
of a deceased joint Shareholder from any and all undertakings in respect of the shares. Any
Person who shall become an owner of shares following the death of a Shareholder shall be
entitled to be registered as owner of such shares after having presented to an officer of
the Company to be designated by the Chief Executive Officer an inheritance order or probation
order or order of appointment of an administrator of estate and any other proof as required
- if these are sufficient in the opinion of such officer - testifying to such Person’s
right to appear as shareholder in accordance with these Articles, and which shall testify
to his title to such shares. The provisions of Article 46 above shall apply, mutatis mutandis
, also in regard to this Article. |
50. | The
receiver or liquidator of a Shareholder who is a company or the trustee in bankruptcy or
the official receiver of a Shareholder who is bankrupt, upon presenting appropriate proof
to the satisfaction of an officer of the Company to be designated by the Chief Executive
Officer that such Shareholder has the right to appear in this capacity and which testifies
to such Shareholder’s title, may, with the consent of the Board of Directors (the Board
of Directors shall not be obligated to give such consent) be registered as the owner of such
shares. Furthermore, such Shareholder may assign such shares in accordance with the rules
prescribed in these Articles. The provisions of Article 46 above shall apply, mutatis
mutandis , also in regard to this Article. |
| |
51. | A
Person entitled to be registered as a Shareholder following assignment pursuant to these
Articles shall be entitled, if approved by the Board of Directors and to the extent and under
the conditions prescribed by the Board of Directors, to dividends and any other monies paid
in respect of the shares, and shall be entitled to give the Company confirmation of the payments;
however, he shall not be entitled to be present or to vote at any General Meeting of the
Company or, subject to the provisions of these Articles, to make use of any rights of Shareholders,
until he has been registered as owner of such shares in the Register. |
GENERAL
MEETING
52. | A
General Meeting shall be held at least once in every year, not later than 15 (fifteen) months
after the last General Meeting, at such time and at such place as the Board of Directors
shall determine. Such General Meeting shall be called an annual meeting, and all other meetings
of the Shareholders shall be called extraordinary meetings. |
| |
53. | The
Board of Directors may call an extraordinary meeting whenever it sees fit to do so. |
| |
54. | The
Board of Directors shall be obliged to call an extraordinary meeting upon a requisition in
writing in accordance with the Companies Law. |
| |
55. | The
Company shall provide prior notice in regard to the holding of an annual meeting or an extraordinary
meeting in accordance with the requirements of these Articles, the Companies Law and the
regulations promulgated thereunder. Subject to the provisions of the Companies Law and the
regulations promulgated thereunder, in counting the number of days of prior notice given,
the day of publication of notice shall not be counted, but the day of the meeting shall be
counted. The notice shall specify those items and contain such information as shall be required
by the Companies Law, the regulations promulgated thereunder and any other applicable law
and regulations. |
| |
56. | Any
Shareholder (a “ Proposing Shareholder”) requesting to add an item to the agenda of a General Meeting may submit such
a request (a “ Proposal Request “) in accordance with the Companies Law. Subject to any requirements under the Law,
to be considered timely and thereby be added to such agenda, a Proposal Request must be delivered, either in person or by certified mail,
postage prepaid, and received at the Office, (i) in the case of a General Meeting that is an annual meeting, no less than sixty (60)
days nor more than one-hundred twenty (120) days prior to the date of the first anniversary of the preceding year’s annual meeting,
provided, however, that, in the event that the date of the annual meeting is advanced more than thirty (30)
days prior to or delayed by more than thirty (30) days after the anniversary of the preceding year’s annual meeting, notice by
the Proposing Shareholder to be timely must be so received not earlier than the close of business one-hundred twenty (120) days prior
to such annual meeting and not later than the close of business on the later of ninety (90) days prior to such annual meeting or the
tenth (10th) day following the day on which public announcement of the date of such meeting is first made, and (ii) in the
case of a General Meeting that is an extraordinary meeting, no earlier than one-hundred twenty (120) days prior to such extraordinary
meeting and no later than sixty (60) days prior to such extraordinary meeting or the tenth (10th) day following the day on
which public announcement of the date of such meeting is first made, subject to applicable law. |
In
no event shall the public announcement of an adjournment or postponement of a General Meeting commence a new time period (or extend any
time period) for the giving of a Shareholder’s notice as described above. Subject to any requirements under the Companies Law,
nominations of persons for election to the Board of Directors may only be made at an extraordinary meeting if directors are to be elected
at such meeting (a) by or at the direction of the Board of Directors, or (b) by any shareholder who is entitled to vote at the meeting
and who complies with the notice procedures set forth in this Article. Such request shall also set forth: (i) the name and address of
the Proposing Shareholder making the request; (ii) a representation that the Proposing Shareholder is a holder of record of shares of
the Company entitled to vote at such meeting and intends to appear in person or by proxy at the meeting; (iii) a description of all arrangements
or understandings between the Proposing Shareholder and any other Person or Persons (naming such Person or Persons) in connection with
the subject which is requested to be included in the agenda; (iv) a description of all Derivative Transactions (as defined below) by
the Proposing Shareholder during the previous twelve (12) month period, including the date of the transactions and the class, series
and number of securities involved in, and the material economic terms of, such Derivative Transactions; and (v) a declaration that all
the information that is required under the Companies Law and any other applicable law to be provided to the Company in connection with
such subject, if any, has been provided. Furthermore, the Board of Directors, may, in its discretion, to the extent it deems necessary,
request that the Proposing Shareholder(s) provide additional information necessary so as to include a subject in the agenda of a General
Meeting, as the Board of Directors may reasonably require.
A
“ Derivative Transaction “ means any agreement, arrangement, interest or understanding entered into by, or on behalf
or for the benefit of, any Proposing Shareholder or any of its affiliates or associates, whether of record or beneficial: (a) the value
of which is derived in whole or in part from the value of any class or series of shares or other securities of the Company, (b) which
otherwise provides any direct or indirect opportunity to gain or share in any gain derived from a change in the value of securities of
the Company, (c) the effect or intent of which is to mitigate loss, manage risk or benefit of security value or price changes, or (d)
which provides the right to vote or increase or decrease the voting power of such Proposing Shareholder, or any of its affiliates or
associates, with respect to any shares or other securities of the Company, which agreement, arrangement, interest or understanding may
include, without limitation, any option, warrant, debt position, note, bond, convertible security, swap, stock appreciation right, short
position, profit interest, hedge, right to dividends, voting agreement, performance-related fee or arrangement to borrow or lend shares
(whether or not subject to payment, settlement, exercise or conversion in any such class or series), and any proportionate interest of
such Proposing Shareholder in the shares or other securities of the Company held by any general or limited partnership, or any limited
liability company, of which such Proposing Shareholder is, directly or indirectly, a general partner or managing member. The information
required pursuant to this Article 56 shall be updated as of the record date of the General Meeting, five (5) business days before the
General Meeting, and any adjournment or postponement thereof.
57. | Subject
to Article 65 below, in the event that the Company has established that an adjourned meeting
shall be held on such date which is later than the date provided for in Section 78(b) of
the Companies Law, such later date shall be included in the notice. The Company may add additional
places for Shareholders to review the full text of the proposed resolutions, including an
internet site. The notice shall be provided in the manner prescribed below under the heading
“Notices” in Articles 128 to 131 below. |
PROCEEDINGS
AT GENERAL MEETING
58. | No
business shall be conducted at a General Meeting unless a quorum is present, and no resolution
shall be passed unless a quorum is present at the time the resolution is voted on. Except
in cases where it is otherwise stipulated, a quorum shall be constituted when there are personally
present, or represented by proxy, at least two (2) Shareholders who hold, in the aggregate,
at least 25% of the voting rights in the Company. A proxy may be deemed to be two (2) or
more Shareholders pursuant to the number of Shareholders he represents. |
59. | If
within half an hour from the time appointed for the meeting, a quorum is not present, without
there being an obligation to notify the Shareholders to that effect, the meeting shall be
adjourned to the same day, in the following week, at the same hour and at the same place
or to a later time and date if so specified in the notice of the meeting, unless such day
shall fall on a statutory holiday (either in Israel or in the United States), in which case
the meeting will be adjourned to the first business day afterwards which is not a statutory
holiday.
|
If
the original meeting was convened upon requisition under Section 63 of the Companies Law, one or more Shareholders, present in person
or by proxy, and holding the number of shares required for making such requisition, shall constitute a quorum at the adjourned meeting,
but in any other case any two (2) Shareholders present in person or by proxy, shall constitute a quorum at the adjourned meeting.
60. | The
Chairman of the Board of Directors, or any other Person appointed for this purpose by the
Board of Directors, shall preside at every General Meeting. If within fifteen (15) minutes
from the time appointed for the meeting, the designated chairman for the meeting shall not
be present, the Shareholders present at the meeting shall elect one of their number or any
other Person to serve as chairman of the meeting. |
| |
61. | Resolutions
at the General Meeting shall be passed in accordance with the definition of “Resolution”
set forth in Article 1.1 above, unless otherwise required by Companies Law or these Articles.
Every vote at a General Meeting shall be conducted according to the number of votes to which
each Shareholder is entitled on the basis of the number of Ordinary Shares held by such Shareholder
(in accordance with the provisions of Article 7.1 above). |
| |
62. | Where
a poll has been demanded, the chairman of the meeting shall be entitled - but not obliged
- to accede to the demand. Where the chairman of the meeting has decided to hold a poll,
such poll shall be held in such manner, at such time and at such place as the chairman of
the meeting directs, either immediately or after an interval or postponement, or in any other
way, and the results of the vote shall be deemed to be the Resolution at the meeting at which
the poll was demanded. A person demanding a poll may withdraw his demand prior to the poll
being held. |
| |
63. | A
demand for the holding of a poll shall not prevent the continued business of the meeting
on all other questions apart of the question in respect of which a poll was demanded. |
| |
64. | The
announcement by the chairman of the meeting that a Resolution has been passed unanimously
or by a particular majority, or has been rejected, and a note recorded to that effect in
the Company’s minute book, shall serve as prima facie proof of such fact, and
there shall be no necessity for proving the number of votes or the proportion of votes given
for or against the Resolution, unless otherwise required under applicable law and regulation. |
| |
65. | The
Chairman of a General Meeting at which a quorum is present may, with the consent of holders
of a majority of the voting power represented in person and by proxy and voting on the question
of adjournment, adjourn the meeting from time to time and from place to place, but no business
shall be transacted at any adjourned meeting except business which might lawfully have been
transacted at the meeting as originally called. Subject to these Articles, it shall not be
necessary to give any notice of an adjournment unless the meeting is adjourned for more than
twenty-one (21) days, in which case notice thereof shall be given in the manner required
for the meeting as originally called. Where a General Meeting has been adjourned without
changing its agenda, to a date which is not more than twenty-one (21) days, notices shall
be given for the new date, as early as possible, and by no later than seventy-two (72) hours
before the General Meeting. |
VOTES
OF SHAREHOLDERS
66. | The
voting rights of every shareholder entitled to vote at a General Meeting shall be as set
forth in Article 7.1 of these Articles. |
| |
67. | In
the case of joint Shareholders, the vote of the senior joint holder, given personally or
by proxy, shall be accepted, to the exclusion of the vote of the remaining joint Shareholders,
and for these purposes the senior of the joint Shareholders shall be the Person amongst the joint holders whose name appears first in the Register.
|
68. | A
Shareholder who is an Incapacitated Person may vote solely through his guardian or other
person who fulfills the function of such guardian and who was appointed by a court, and any
guardian or other person as aforesaid shall be entitled to vote by way of a proxy, or in
such manner as the court directs. |
69. | Any
corporation which is a Shareholder of the Company shall be entitled, by way of resolution
of its board of directors or another organ which manages said corporation, to appoint such
person which it deems fit, whether or not such person is a Shareholder of the Company, to
act as its representative at any General Meeting of the Company or at a meeting of a class
of shares in the Company which such corporation is entitled to attend and to vote thereat,
and the appointed as aforesaid shall be entitled, on behalf of the corporation whom he represents,
to exercise all of the same powers and authorities which the corporation itself could have
exercised had it been a natural person holding shares of the Company. |
70. | Every
Shareholder who is entitled to attend and vote at a General Meeting of the Company, shall
be entitled to appoint a proxy. A proxy can be appointed by more than one Shareholder, and
vote in different ways on behalf of each principal. |
The
instrument appointing a proxy shall be in writing signed by the Person making the appointment or by his authorized representative, and
if the Person making the appointment is a corporation, the power of attorney shall be signed in the manner in which the corporation signs
on documents which bind it, and a certificate of an attorney with regard to the authority of the signatories to bind the corporation
shall be attached thereto. The proxy need not be a shareholder of the Company.
71. | The
instrument appointing a proxy, or a copy thereof certified by an attorney, shall be lodged
at the Office, or at such other place as the Board of Directors shall specify, not less than
forty- eight (48) hours prior to the meeting at which the proxy intends to vote based on
such instrument of proxy. Notwithstanding the above, the chairman of the meeting shall have
the right to waive the time requirement provided above with respect to all instruments of
proxies and to accept any and all instruments of proxy until the beginning of a General Meeting.
A document appointing a proxy shall be valid for every adjourned meeting of the meeting to
which the document relates. |
72. | Every
instrument appointing a proxy, whether for a meeting specifically indicated, or otherwise,
shall, as far as circumstances permit, be substantially in the following form, or in any
other form approved by the Board of Directors: |
I
of being a shareholder holding voting shares in Vascular Biogenics Ltd., hereby appoint Mr. of or failing him, Mr. of , or failing him,
Mr. of , to vote in my name, place and stead at the (ordinary/extraordinary) General Meeting of the Company to be held on the of 20 , and
at any adjourned meeting thereof.
In
witness whereof I have hereto set my hand on the day of .
73. | No
Shareholder shall be entitled to vote at a General Meeting unless he has paid all of the
calls and all of the amounts due from him, for the time being, in respect of his shares. |
74. | A
vote given in accordance with the instructions contained in an instrument appointing a proxy
shall be valid notwithstanding the death or bankruptcy of the appointer, or the revocation
of the proxy, or the transfer of the share in respect of which the vote was given as aforesaid,
unless notice in writing of the death, revocation or transfer is received at the Office,
or by the chairman of the meeting, prior to such vote. |
75. | Subject
to the Companies Law, an instrument appointing a proxy shall be deemed revoked (i)
upon receipt by the Company or the chairman of the meeting, subsequent to receipt by the Company of such instrument, of written notice
signed by the person signing such instrument or by the Shareholder appointing such proxy canceling the appointment thereunder (or the
authority pursuant to which such instrument was signed) or of an instrument appointing a different proxy, provided such notice of cancellation
or instrument appointing a different proxy were so received at the place and within the time for delivery of the instrument revoked thereby
as referred to in Article 71 hereof, or (ii) if the appointing shareholder is present in person at the meeting for which such instrument
of proxy was delivered, upon receipt by the chairman of such meeting of written notice from such shareholder of the revocation of such
appointment, or if and when such Shareholder votes at such meeting. A vote cast in accordance with an instrument appointing a proxy shall
be valid notwithstanding the revocation or purported cancellation of the appointment, or the presence in person or vote of the appointing
Shareholder at a meeting for which it was rendered, unless such instrument of appointment was deemed revoked in accordance with the foregoing
provisions of this Article 75 at or prior to the time such vote was cast. |
THE
BOARD OF DIRECTORS
76. | Unless
otherwise resolved by a Resolution, the prescribed number of Directors of the Company shall
be up to nine (9) (including the External Directors), as may be fixed, from time to time,
by the Board of Directors. At any time the minimum number of Directors (other than the External
Directors) shall not fall below three (3). Any Director shall be eligible for re- election
upon termination of his term of office, subject to applicable law. |
| 77.1. | Prior
to every annual General Meeting of the Company, the Board of Directors of the Company (or
a Committee of Directors) shall select, via a resolution adopted by a majority of the Board
of Directors (or such committee), a number of persons to be proposed to the Shareholders
for election as directors of the Company at such annual General Meeting for service until
the annual General Meeting to be held in the next year following the year of their election
(the “Nominees”). Any shareholder entitled under applicable law to nominate
one or more persons for election as directors at a General Meeting (each such person, an
“Alternate Nominee”) may make such nomination only if a written notice
of such shareholder’s intent to make such nomination or nominations has been given
to the Secretary of the Company (or, if there is no such Secretary, the Chief Executive Officer).
Each such notice shall set forth: (a)
the name and address of the shareholder who intends to make the nomination and of the Alternate Nominees; (b) a representation that the
shareholder is a holder of record of shares of the Company entitled to vote at such meeting (including the number of shares held of record
by the shareholder) and intends to appear in person or by proxy at the meeting to nominate the Alternate Nominees; (c) a description
of all arrangements or understandings between the shareholder and each Alternate Nominee and any other person or persons (naming such
person or persons) pursuant to which the nomination or nominations are to be made by the shareholder; and (d) the consent of each Alternate
Nominee to serve as a director of the Company if so elected and a declaration signed by each Alternate Nominee declaring that there is
no limitation under the Companies Law for the appointment of such a nominee and that all of the information that is required under the
Companies Law to be provided to the Company in connection with such an appointment has been provided. The Board of Directors may refuse
to acknowledge the nomination of any person not made in compliance with the foregoing procedure. |
| 77.2. | The
Nominees or Alternate Nominees shall be elected by a Resolution at the annual General Meeting
at which they are subject to election. |
| 77.3. | Every
director shall hold office until the end of the next annual General Meeting following the
annual General Meeting at which he was elected, unless his office is vacated in accordance
with Article 79 or Article 82 below. If, at an annual General Meeting, no Nominees or Alternate
Nominees are elected, the directors then in office shall continue to hold office until the
convening of a General Meeting at which Nominees or Alternate Nominees shall be elected. |
| 77.4. | If
the office(s) of members(s) of the Board of Directors shall be vacated, the remaining members
of the Board of Directors shall be entitled to appoint additional director(s) in place of
the director(s) whose office(s) have been vacated, for a term of office equal to the remaining
period of the term of office of the director(s) whose office(s) have been vacated. |
78. | The
Directors in their capacity as such shall be entitled to receive remuneration as shall be
determined in compliance with the Companies Law and the regulations promulgated thereunder.
The conditions (including remuneration) of the terms of office of members of the Board of
Directors shall be decided by the Board of Directors and/or any committee thereof, but the
same shall be valid only if ratified in the manner required under the Companies Law.
The remuneration of Directors may be fixed as an overall payment or other consideration and/or as a payment or other consideration in
respect of attendance at meetings of the Board of Directors. In addition to his remuneration, each Director shall be entitled to be reimbursed,
retroactively or in advance, in respect of his reasonable expenses connected with performing his functions and services as a Director.
Such entitlement shall be determined in accordance with, and shall be subject to, a specific resolution or policy adopted by the Board
of Directors regarding such matter and in accordance with the requirements of applicable law. |
| 79.1. | Subject
to the provisions of the Companies Law with regard to External Directors and subject to Article
77 above and Article 82 below, the office of a member of the Board of Directors shall be
vacated in any one of the following events: |
| 79.1.1. | if
he resigns his office by way of a letter signed by him, lodged at the Office; |
| 79.1.2. | if
he is declared bankrupt; |
| 79.1.3. | if
he becomes insane or unsound of mind; |
| 79.1.5. | if
he is prevented by applicable law from serving as a Director of the Company; |
| 79.1.6. | if
the Board terminates his office according to Section 231 of the Companies Law; |
| 79.1.7. | if
a court order is given in accordance with Section 233 of the Companies Law; |
| 79.1.8. | if
he is removed from office by a Resolution at a General Meeting of the Company adopted by
a majority of the voting power in the Company; or |
| 79.1.9. | if
his period of office has terminated in accordance with the provisions of these Articles. |
| 79.2. | If
the office of a member of the Board of Directors should be vacated, the remaining members
of the Board of Directors shall be entitled to act for all purposes, for as long as their
number does not fall below the minimum, for the time being, specified for the Directors,
as prescribed in Article 76 above. Should their number fall below the aforesaid minimum,
the Directors shall not be entitled to act, except for the appointment of additional directors,
or for the purpose of calling a General Meeting for the appointment of additional directors,
or for the purpose of calling a General Meeting for the appointment of a new Board of Directors. |
| 79.3. | The
office of an External Director shall be vacated only in accordance with the provisions for
the vacation of office and the removal of External Directors under the Companies Law. |
OTHER
PROVISIONS REGARDING DIRECTORS
| 80.1. | Subject
to any mandatory provisions of applicable law, a Director shall not be disqualified by virtue
of his office from holding another office in the Company or in any other company in which
the Company is a shareholder or in which it has any other form of interest, or of entering
into a contract with the Company, either as seller or buyer or otherwise. Likewise, no contract
made by the Company or on its behalf in which a Director has any form of interest may be
nullified and a Director shall not be obliged to account to the Company for any profit deriving
from such office, or resulting from such contract, merely by virtue of the fact that he serves
as a Director or by reason of the fiduciary relationship thereby created, but such Director
shall be obliged to disclose to the Board of Directors the nature of any such interest at
the first opportunity. |
A
general notice to the effect that a Director is a shareholder or has any other form of interest in a particular firm or a particular
company and that he must be deemed to have an interest in any business with such firm or company shall be deemed to be adequate disclosure
for purposes of this Article in relation to such Director, and after such general notice has been given, such Director shall not be obliged
to give special notice in relation to any particular business with such firm or such company.
| 80.2. | Subject
to the provisions of the Companies Law and these Articles, the Company shall be entitled
to enter into a transaction in which an Office Holder of the Company has a personal interest,
directly or indirectly, and may enter into any contract or otherwise transact any business
with any third party in which contract or business an Office Holder has a personal interest,
directly or indirectly. |
81. | The
Board of Directors shall elect one (1) or more of its members to serve as the Chairman of
the Board of Directors (the “ Chairman of the Board of Directors “), provided
that, subject to the provisions of Section 121(c) of the Companies Law, the Chief Executive
Officer of the Company shall not serve as Chairman of the Board of Directors. The office
of Chairman of the Board of Directors shall be vacated in each of the cases mentioned in
Articles 79.1 above and 82 below. The Board of Directors may also elect one or more members
to serve as Vice Chairman, who shall have such duties and authorities as the Board of Directors
may assign to him or her. |
82. | Subject
to the relevant provisions of the Companies Law, the Company may, in a General Meeting, by
a Resolution adopted by a majority of the voting power in the Company, dismiss any Director,
prior to the end of his term of office and the Board of Directors shall be entitled, by regular
majority, with the exception of the External Directors who shall be appointed and removed
in accordance with the Companies Law, to appoint another individual in his place as a Director.
The individual so appointed shall hold such office only for that period of time during which
the director whom he replaces would have held office. |
83. | A
Director shall not be obliged to hold any share in the Company. |
CHIEF
EXECUTIVE OFFICER
| 84.1. | The
Board of Directors shall, from time to time, appoint a Chief Executive Officer and subject
to the provisions of the Companies Law delineate his powers and authorities and his remuneration.
Subject to any contract between the Chief Executive Officer and the Company, the Board of
Directors may dismiss him or replace him at any time it deems fit.
|
| 84.2. | A
Chief Executive Officer need not be a Director or Shareholder. |
Subject
to the provisions of any contract between the Chief Executive Officer and the Company, if the Chief Executive Officer is also a Director,
all of the same provisions with regard to appointment, resignation and removal from office shall apply to the Chief Executive Officer
in his capacity as a Director, as apply to the Company’s other Directors.
| 84.3. | The
Board of Directors shall be entitled from time to time to delegate to the Chief Executive
Officer for the time being such of the powers it has pursuant to these Articles as they deem
appropriate, and the Board of Directors shall be entitled to grant such powers for such period
and for such purposes and on such conditions and with such restrictions as it deem appropriate,
and it shall be entitled to grant such powers without renouncing the powers and authorities
of the Board of Directors in such regard, and it may, from time to time, revoke, annul and
alter such delegated powers and authorities, in whole or in part. |
| 84.4. | Subject
to the provisions of any applicable law, the remuneration of the Chief Executive Officer
shall be fixed from time to time by the Board of Directors (and, so long as required by the
Companies Law, shall be approved by the Compensation Committee and by the Shareholders unless
exempted from Shareholders approval) and such remuneration may be in the form of a fixed
salary or commissions or a participation in profits, or in any other manner which may be
decided by the Board of Directors (and approved according to this Article 84.4). |
PROCEEDINGS
OF THE BOARD OF DIRECTORS
| 85.1. | The
Board of Directors shall convene for a meeting at least once every fiscal quarter. |
| 85.2. | The
Board of Directors may meet in order to exercise its powers pursuant to Section 92 of the
Companies Law, including without limitation to supervise the Company’s affairs, and
it may, subject to the provisions of the Companies Law,adjourn
its meetings and regulate its proceedings and operations as it deems fit. It may also prescribe the quorum required for the conduct of
business. Until otherwise decided a quorum shall be constituted if a majority of the Directors holding office for the time being are
present. |
| 85.3. | Should
a Director or Directors be barred from being present and voting at a meeting of the Board
of Directors pursuant to Section 278 of the Companies Law, the quorum shall be a majority
of the Directors entitled to be present and to vote at the meeting of the Board of Directors. |
86. | Any
Director, the Chief Executive Officer or the auditor of the Company in the event stipulated
in Section 169 of the Companies Law, may, at any time, demand the convening of a meeting
of the Board of Directors. The Chairman of the Board shall be obliged, on such demand, to
call such meeting on the date requested by the Director, the Chief Executive Officer or the
auditor of the Company soliciting such a meeting, provided that proper notice pursuant to
Article 87 is given. |
87. | Every
Director shall be entitled to receive notice of meetings of the Board of Directors, and such
notice may be in writing or by facsimile, or electronic mail, sent to the last address (whether
physical or electronic) or facsimile number given by the Director for purposes of receiving
notices, provided that the notice shall be given at least a reasonable amount of time prior
to the meeting and in no event less than 48 (forty eight) hours prior notice, unless the
urgency of the matter(s) to be discussed at the meeting reasonably require(s) a shorter notice
period. |
88. | Every
meeting of the Board of Directors at which a quorum is present shall have all the powers
and authorities vested for the time being in the Board of Directors. |
89. | Questions
which arise at meetings of the Board of Directors shall be decided by a simple majority of
the members of the Board of Directors attending such meeting and voting on such matter. Each
Director shall have one vote when voting at the Board of Directors. In the case of an equality
of votes of the Board of Directors, the Chairman of the Board of Directors shall not have
a second or casting vote, and the proposal shall be deemed to be defeated. |
If
the Chairman of the Board of Directors is not present within 30 (thirty) minutes after the time appointed for the meeting, the Directors
present shall elect one of their members to preside at such meeting.
90. | The
Board of Directors may adopt resolutions, without actually convening a meeting of the Board
of Directors, provided that all the Directors entitled to participate in the meeting and
to vote on the subject brought for decision agree thereto. If resolutions are made as stated
in this Article 90, the Chairman of the Board of Directors shall record minutes of the decisions
stating the manner of voting of each Director on the subjects brought for decision, as well
as the fact that all the Directors agreed to take the decision without actually convening. |
91. | The
Board of Directors may hold meetings by use of any means of communication, on condition that
all participating Directors can hear each other at the same time. In the case of a resolution
passed by way of a telephone call or any such other means of communication, a copy of the
text of the resolution shall be sent, as soon as possible thereafter, to the Directors. |
GENERAL
POWERS OF THE BOARD OF DIRECTORS
92. | The
supervision of the Company’s affairs shall be in the hands of the Board of Directors,
which shall be entitled to exercise all of the powers and authorities to perform any act
and deed which the Company is entitled to exercise and to perform in accordance with these
Articles or according to the Companies Law, and in respect of which there is no provision
or requirement in these Articles, or in the Companies Law or/and in the U.S. Rules, that
such powers and authorities may be exercised or done by the Shareholders in a General Meeting
or by a Committee of Directors. |
93. | The
Board of Directors may, as it deems fit and subject to any applicable law, delegate to a
committee (a “ Committee of Directors “) certain of its powers and authorities,
in whole or in part (as appropriate). The curtailment or revocation of the powers and authorities
of a Committee of Directors by the Board of Directors shall not invalidate a prior act of
such Committee of Directors or an act taken in accordance with its instructions, which would
have been valid had the powers and authorities of the Committee of Directors not been altered
or revoked by the Board of Directors. Subject to applicable law, a Committee of Directors
may be comprised of one (1) Director or of several Directors, and in the case of a Committee
of Directors that is appointed to advise the Board of Directors only, persons who are not
Directors may be appointed to it. |
94. | The
meetings and proceedings of every such Committee of Directors which is comprised of 2 (two)
or more members shall be conducted in accordance with the provisions contained in these Articles
in regard to the conduct of meetings and proceedings of the Board of Directors to the extent
that the same are suitable for such committee, and so long as no provisions have been adopted
in replacement thereof by the Board of Directors. |
RATIFICATION
OF ACTIONS
95. | Subject
to the Companies Law, all acts taken in good faith by the Board of Directors and/or a Committee
of Directors or by an individual acting as a member thereof shall be valid even if it is
subsequently discovered that there was a defect in the appointment of the Board of Directors,
the Committee of Directors or the member, as the case may be, or that the members, or one
of them, was/were disqualified from being appointed as a Director/s or to a Committee of
Directors. |
| 96.1. | The
Board of Directors or any Committee of Directors may ratify any act the performance of which
at the time of the ratification was within the scope of the authority of the Board of Directors
or the relevant Committee of Directors. |
| 96.2. | The
General Meeting shall be entitled to ratify any act taken by the Board of Directors and/or
any Committee of Directors without authority or which was tainted by some other defect. |
| 96.3. | From
the time of the ratification, every act ratified as aforesaid, shall be treated as though
lawfully performed from the outset. |
97. | The
Board of Directors may, from time to time, in its absolute discretion, borrow or secure any
amounts of money required by the Company for the conduct of its business. |
98. | The
Board of Directors shall be entitled to raise or secure the repayment of an amount obtained
by them, in such way and on such conditions and times as they deem fit. The Board of Directors
shall be entitled to issue documents of undertaking, such as options, debentures or debenture
stock, whether linked or redeemable, convertible debentures or debentures convertible into
other securities, or debentures which carry a right to purchase shares or to purchase other
securities, or any mortgage, pledge, collateral or other charge over the property of the
Company and its undertaking, in whole or in part, whether present or future, including the
uncalled share capital or the share capital which has been called but not yet paid. |
The
deeds of undertaking, debentures of various types or other forms of collateral security may be issued at a discount, at a premium or
otherwise and with such preferential or deferred or other rights, as the Board of Directors shall, from time to time, decide.
SIGNING
POWERS
99. | Subject
to any other resolution on the subject passed by the Board of Directors, the Company shall
be bound only pursuant to a document in writing bearing its seal or its rubber stamp or its
printed name, and the signature of whomever may be authorized by the Board of Directors,
which shall be entitled to empower any person, either alone or jointly with another, even
if he is not a Shareholder or a Director, to sign and act in the name and on behalf of the
Company. |
100. | The
Board of Directors shall be entitled to prescribe separate signing power in regard to different
businesses of the Company and in respect of the limit of the amounts in respect of which
various persons shall be authorized to sign. |
SECRETARY,
OFFICE-HOLDERS, CLERKS AND REPRESENTATIVES
101. | The
Board of Directors shall be entitled, from time to time, to appoint, or to delegate to the
Chief Executive Officer, either alone or together with other persons designated by the Board
of Directors, the ability to appoint Office Holders (other than Directors), a Secretary for
the Company, employees and agents to such permanent, temporary or special positions, and
to specify and change their titles, authorities and duties, and may set, or delegate to the
Chief Executive Officer, either alone or together with other persons designated by the Board
of Directors, the ability to set salaries, bonuses and other compensation of any employee
or agent who is not an Office Holder. Salaries, bonuses and compensation of Office Holders
who are not Directors shall be determined and approved by the Chief Executive Officer, and/or
in such other manner as may be required from time to time under the Companies Law. The Board
of Directors, or the Chief Executive Officer, either alone or together with other persons
designated by the Board of Directors, (in the case of any Office Holder, employee or agent
appointed thereby), shall be entitled at any time, in its, his or their (as applicable) sole
and absolute discretion, to terminate the services of one of more of the foregoing persons
(in the case of a Director, however, subject to compliance with Article 79 above), subject
to any other requirements under applicable law. |
102. | The
Board of Directors and the Chief Executive Officer may from time to time and at any time,
subject to their powers under these Articles and the Companies Law, empower any person to
serve as representative of the Company for such purposes and with such powers and authorities,
instructions and discretions for such period and subject to such conditions as the Board
of Directors (or the Chief Executive Officer, as the case may be) shall deem appropriate.
Consistent with the preceding sentence, the Board of Directors (or the Chief Executive Officer,
as the case may be) may grant such person, inter alia , the power to transfer the
authority, powers and discretions vested in him, in whole or in part. The Board of Directors
may (or the Chief Executive Officer, as the case may be), from time to time, revoke, annul,
vary or change any such power or authority, or all such powers or authorities collectively. |
DIVIDENDS,
BONUS SHARES, FUNDS AND CAPITALIZATION OF FUNDS AND PROFITS
103. | Unless
otherwise permitted by the Companies Law, no dividends shall be paid other than out of the
Company’s profits available for distribution as set forth in the Companies Law. |
104. | The
Board of Directors may decide on the payment of a dividend or on the distribution of bonus
shares. |
105. | A
dividend in cash or bonus shares shall be paid or distributed, as the case may be, equally
to the holders of the Ordinary Shares registered in the Register, pro rata to the nominal
amount of capital paid up or credited as paid up on par value of the shares, without reference
to any premium which may have been paid thereon. However, whenever the rights attached to
any shares or the terms of issue of the shares do not provide otherwise, an amount paid on
account of a share prior to the payment thereof having been called, or prior to the due date
for payment thereof, and on which the Company is paying interest, shall not be taken into
account for purposes of this Article as an amount paid-up on account of the share. |
106. | Unless
other instructions are given, it shall be permissible to pay any dividend by way of a check
or payment order to be sent by post to the registered address of the Shareholder or the Person
entitled thereto, or in the case of joint Shareholders being registered, to the Shareholder
whose name appears first in the Register in relation to the joint shareholding. Every such
check shall be made in favor of the Person to whom it is sent. A receipt by the Person whose
name, on the date of declaration of the dividend, was registered in the Register as the owner
of the shares, or in the case of joint holders, by one of the joint holders, shall serve
as a discharge with regard to all the payments made in connection with such share. |
The
Board of Directors shall be entitled to invest any dividend which has not been claimed for a period of one (1) year after having
been declared, or to make use thereof in any other way for the benefit of the Company until such time as it is claimed. The Company
shall not be obliged to pay interest or linkage in respect of an unclaimed dividend. The payment by the Board of Directors of any
unclaimed dividend into a separate account shall not constitute the Company a trustee in respect thereof, and any dividend unclaimed
after a period of seven (7) years from the date of declaration of such dividend, shall be forfeited and shall revert to the
Company, provided, however, that the Board of Directors may, at its discretion, cause the Company to pay any such dividend, or any
part thereof, to a person who would have been entitled thereto had the same not reverted to the Company.
107. | Unless
otherwise specified in the terms of issue of shares or securities convertible into, or which
grant a right to purchase, shares, any shares that are fully paid-up or credited as paid-up
shall at any time confer on their holders the right to participate in the full dividends
and in any other distribution for which the determining date for the right to receive the
same is the date at which the aforesaid shares were fully paid-up or credited as fully paid-up,
as the case may be, or subsequent to such date. |
108. | A
dividend or other beneficial rights in respect of shares shall not bear interest. |
109. | The
Board of Directors shall be entitled to deduct from any dividend or other beneficial rights,
all amounts of money which the holder of the share in respect of which the dividend is payable
or in respect of which the other beneficial rights were given, may owe to the Company in
respect of such share, whether or not the due date for payment thereof has arrived. |
110. | The
Board of Directors shall be entitled to retain any dividend or bonus shares or other beneficial
rights in respect of a share in relation to which the Company has a lien, and to utilize
any such amount or the proceeds received from the sale of any bonus shares or other beneficial
rights, for the discharge of the debts or liabilities in respect of which the Company has
a lien. |
111. | The
Board of Directors may decide that a dividend is to be paid, in whole or in part, by way
of a distribution of assets of the Company in kind, including by way of debentures or debenture
stock of the Company, or shares or debentures or debenture stock of any other company, or
in any other way. |
| 112.1. | The
Board of Directors may, at any time and from time to time, decide that any portion of the
amounts standing for the time being to the credit of any capital fund (including a fund created
as a result of a revaluation of the assets of the Company), or which are held by the Company
as profits available for distribution, shall be capitalized for distribution subject to and
in accordance with the provisions of the Companies Law and of these Articles, amongst those
Shareholders who are entitled thereto and pro rata to their entitlement under these Articles,
provided that the same shall not be paid in cash but shall serve for the payment up in full
either at par or with a premium as prescribed by the Company, of shares which have not yet
been issued or of debentures of the Company which shall be allotted and distributed amongst
the Shareholders in the aforesaid ratio as fully paid-up shares or debentures. |
| 112.2. | The
Board of Directors shall be entitled to distribute bonus shares and to decide that the bonus
shares shall be of the same class which confers on the Shareholders or the Persons entitled
thereto the right to participate in the distribution of bonus shares, or may decide that
the bonus shares shall be of a uniform class to be distributed to each of the Shareholders
or Persons entitled to shares as aforesaid, without reference to the class of shares conferring
the right to participate in the distribution on the holders of the shares or the Persons
entitled thereto as aforesaid. |
| 113.1. | In
every case that the Company issues bonus shares by way of a capitalization of profits or
funds at a time at which securities issued by the Company are in circulation and confer on
the holders thereof rights to convert the same into shares in the share capital of the Company,
or options to purchase shares in the share capital of the Company (such rights of conversion
or options shall henceforth be referred to as the “ Rights “), the Board
of Directors shall be entitled (in a case that the Rights or part thereof shall not be otherwise
adjusted in accordance with the terms of their issue) to transfer to a special fund designated
for the distribution of bonus shares in the future (to be called by any name that the Board
of Directors may decide on and which shall henceforth be referred to as the “ Special
Fund “) an amount equivalent to the nominal amount of the share capital to which
some or all of the Rights holders would have been entitled as a result of the issue of bonus
shares, had they exercised their Rights prior to the determining date for the right to receive
bonus shares, including rights to fractions of bonus shares, and in the case of a second
or additional distribution of bonus shares in respect of which the Company acts pursuant
to this Article, including entitlement stemming from a previous distribution of bonus shares. |
| 113.2. | In
the case of the allotment of shares by the Company as a consequence of the exercise of entitlement
by the owners of shares in those cases in which the Board of Directors has made a transfer
to the Special Fund in respect of the Rights pursuant to Article 113.1 above, the Board of
Directors shall allot to each such shareholder, in addition to the shares to which he is
entitled by virtue of having exercised his rights, such number of fully paid-up shares the
nominal value of which is equivalent to the amount transferred to the Special Fund in respect
of his rights, by way of a capitalization to be effected by the Board of Directors of an
appropriate amount out of the Special Fund. The Board of Directors shall be entitled to decide
on the manner of dealing with rights to fractions of shares in its sole discretion. |
| | |
| 113.3. | If
after any transfer to the Special Fund has been made the Rights should lapse, or the period
should end for the exercise of Rights in respect of which the transfer was effected without
such Rights being exercised, then any amount which was transferred to the Special Fund in
respect of the aforesaid unexercised Rights shall be released from the Special Fund, and
the Company may deal with the amount so released in any manner it would have been entitled
to deal therewith had such amount not been transferred to the Special Fund. |
114. | For
the implementation of any resolution regarding a distribution of shares or debentures by
way of a capitalization of profits as aforesaid, the Board of Directors may: |
| 114.1. | Resolve
any difficulty which arises or may arise in regard to the distribution in such manner as
it deems fit and may take all of the steps that it deems appropriate in order to overcome
such difficulty. |
| 114.2. | Issue
certificates in respect of fractions of shares, or decide that fractions of less than an
amount to be decided by the Board of Directors shall not be taken into account for purposes
of adjusting the rights of the Shareholders or may sell the fractions of shares and pay the
proceeds (net) to the Persons entitled thereto. |
| 114.3. | Sign,
or appoint a Person to sign, on behalf of the Shareholders on any contract or other document
which may be required for purposes of giving effect to the distribution, and, in particular,
shall be entitled to sign or appoint a Person who shall be entitled to appoint and submit
a contract as referred to in Section 291 of the Companies Law. |
| 114.4. | Make
any arrangement or other scheme which is required in the opinion of the Board of Directors
in order to facilitate the distribution. |
115. | The
Board of Directors shall be entitled, as it deems appropriate and expedient, to appoint trustees
or nominees for those registered Shareholders who have failed to notify the Company of a
change of their address and who have not applied to the Company in order to receive dividends,
shares or debentures out of capital, or other benefits during the aforesaid period. Such
trustees or nominees shall be appointed for the use, collection or receipt of dividends,
shares or debentures out of capital and rights to subscribe for shares which have not yet
been issued and which are offered to the Shareholders but they shall not be entitled to transfer
the shares in respect of which they were appointed, or to vote on the basis of holding such
shares. In all of the terms and conditions governing such trusts and the appointment of such
nominees it shall be stipulated by the Company that upon the first demand by a beneficial
holder of a share being held by the trustee or nominee, such trustee or nominee shall be
obliged to return to such shareholder the share in question and/or all of those rights held
by it on the Shareholder’s behalf (all as the case may be). Any act or arrangement
effected by any such nominees or trustee and any agreement between the Board of Directors
and a nominee or trustee shall be valid and binding in all respects. |
116. | The
Board of Directors may from time to time prescribe the manner for payment of dividends or
the distribution of bonus shares and the arrangement connected therewith. Without derogating
from the generality of the foregoing, the Board of Directors shall be entitled to pay any
dividends or moneys in respect of shares by sending a check via the mails to the address
of the holder of registered shares according to the address registered in the register of
Shareholders. Any dispatch of a check as aforesaid shall be done at the risk of the shareholder. |
In
those cases in which the Board of Directors specifies the payment of a dividend, distribution of shares or debentures out of capital,
or the grant of a right to subscribe for shares which have not yet been issued and which are offered to the Shareholders against the
delivery of an appropriate coupon attached to any share certificate, such payment, distribution or grant of right to subscribe against
a suitable coupon to the holder of such coupon, shall constitute a discharge of the Company’s debt in respect of such operation
as against any person claiming a right to such payment, distribution or grant of right to subscribe, as the case may be.
117. | If
two (2) or more Persons are registered as joint holders of a share, each of them shall be
entitled to give a valid receipt in respect of any dividend, share or debenture out of capital,
or other moneys, or benefits, paid or granted in respect of such share. |
BOOKS
OF THE COMPANY
118. | The
Board of Directors shall comply with all the provisions of the Companies Law in regard to
the recording of charges and the keeping and maintaining of a register of directors, register
of Shareholders and register of charges. |
119. | Any
book, register and record that the Company is obliged to keep in accordance with the Companies
Law or pursuant to these Articles shall be recorded in a regular book, or by digital, electronic
or other means, as the Board of Directors shall decide. |
120. | Subject
to and in accordance with the provisions of Sections 138 and 139 of the Companies Law, the
Company may cause supplementary registers to be kept in any place outside Israel as the Board
of Directors may deem fit, and, subject to all applicable requirements of the Companies Law,
the Board of Directors may from time to time adopt such rules and procedures as it may deem
fit in connection with the keeping of such supplementary registers. |
BOOKS
OF ACCOUNT
121. | The
Board of Directors shall keep proper books of account in accordance with the provisions of
the Companies Law. The books of account shall be kept at the Office, or at such other place
or places as the Board of Directors shall deem appropriate, and shall at all times be open
to the inspection of members of the Board of Directors. A Shareholder of the Company who
is not a member of the Board of Directors shall not have the right to inspect any books or
accounts or documents of the Company, unless such right has been expressly granted to him
by the Companies Law, or if he has been permitted to do so by the Board of Directors or by
the Shareholders based on a Resolution adopted at a General Meeting. |
122. | The
Board of Directors shall arrange and submit for discussion at the General Meeting the financial
information prescribed under the Companies Law and any regulations promulgated thereunder. |
123. | At
least once each year the accounts of the Company and the correctness of the statement of
income and the balance sheet shall be audited and confirmed by an independent auditor or
auditors. |
124. | The
Company shall, in an annual General Meeting, appoint an independent auditor or auditors who
shall hold such position until the next annual General Meeting, and their appointment, remuneration
and rights and duties shall be subject to the provisions of the Companies Law, provided,
however, that in exercising its authority to fix the remuneration of the auditor(s), the
Shareholders in an annual General Meeting may, by a Resolution, act (and in the absence of
any action in connection therewith shall be deemed to have so acted) to authorize the Board
of Directors to fix such remuneration subject to such criteria or standards, if any, as may
be provided in such Resolution, and if no such criteria or standards are so provided, such
remuneration shall be fixed in an amount commensurate with both the volume and nature of
the services rendered by the auditor(s). By an act appointing such auditors, the Company
may appoint the auditor(s) to serve for a period of up to the end of completion of the audit
of the yearly financial statements for the three (3) year period then ended. |
125. | The
auditors shall be entitled to receive notices of every General Meeting of the Company and
to attend such meetings and to express their opinions on all matters pertaining to their
function as the auditors of the Company. |
126. | Subject
to the provisions of the Companies Law and the U.S. Rules, any act carried out by the auditors
of the Company shall be valid as against any person doing business in good faith with the
Company, notwithstanding any defect in the appointment or qualification of the auditors. |
127. | For
as long as the Company is a Public Company, as defined in the Companies Law, it shall appoint
an internal auditor possessing the authorities set forth in the Companies Law. The internal
auditor of the Company shall present all of its proposed work plans to the Audit Committee
of the Board of Directors, which shall have the authority to approve them, subject to any
modifications in its discretion. |
NOTICES
| 128.1. | The
Company may serve any written notice or other document on a Shareholder by way of delivery
by hand, by facsimile transmission or by dispatch by prepaid registered mail to his address
as recorded in the Register, or if there is no such recorded address, to the address given
by him to the Company for the sending of notices to him. Notwithstanding the foregoing or
any other provision to the contrary contained herein, notices or any other information or
documents required to be delivered to a Shareholder shall be deemed to have been duly delivered
if submitted, published, filed or lodged in any manner prescribed by applicable law. With
respect to the manner of providing such notices or other disclosures, the Company may distinguish
between the Shareholders listed on its regular Registry and those listed in any “additional
registry”, as defined in Section 138(a) of the Companies Law, administered by a transfer
agent or stock exchange registration company. |
| 128.2. | Any
Shareholder may serve any written notice or other document on the Company by way of delivery
by hand at the Office, by facsimile or email transmission to the Company or by dispatch by
prepaid registered mail to the Company at the Office. |
| 128.3. | Any
notice or document which is delivered or sent to a Shareholder in accordance with these Articles
shall be deemed to have been duly delivered and sent in respect of the shares held by him
(whether in respect of shares held by him alone or jointly with others), notwithstanding
the fact that such Shareholder has died or been declared bankrupt at such time (whether or
not the Company knew of his death or bankruptcy), and shall be deemed to be sufficient delivery
or dispatch to heirs, trustees, administrators or transferees and any other persons (if any)
who have a right in the shares. |
| 128.4. | Any
such notice or other document shall be deemed to have been served: |
| 128.4.1. | in
the case of mailing, 48 hours after it has been posted, or when actually received by the
addressee if sooner than 48 hours after it has been posted; |
| 128.4.2. | in
the case of overnight air courier, on the next day following the day sent, with receipt confirmed
by the courier, or when actually received by the addressee if sooner; |
| 128.4.3. | in
the case of personal delivery, when actually tendered in person to such Shareholder; |
| 128.4.4. | in
the case of facsimile or other electronic transmission (including email), the next day following
the date on which the sender receives automatic electronic confirmation by the recipient’s
facsimile machine or computer or other device that such notice was received by the addressee;
or |
| 128.4.5. | in
the case a notice is, in fact, received by the addressee, when received, notwithstanding
that it was defectively addressed or failed, in some other respect, to comply with the provisions
of this Article 128. |
129. | Any
Shareholder whose address is not described in the Register, and who shall not have designated
in writing an address for the receipt of notices, shall not be entitled to receive any notice
from the Company. In the case of joint holders of a share, the Company shall be entitled
to deliver a notice by dispatch to the joint holder whose name stands first in the Register
in respect of such share. |
130. | Whenever
it is necessary to give notice of a particular number of days or a notice for another period,
the day of delivery shall be counted in the number of calendar days or the period, unless
otherwise specified. |
131. | Notwithstanding
anything to the contrary contained herein, notice by the Company of a General Meeting, containing
the information required to be set forth in such notice under these Articles, which is published,
within the time otherwise required for giving notice of such meeting, in: |
| 131.1. | at
least two daily newspapers in the State of Israel shall be deemed to be notice of such meeting
duly given, for the purposes of these Articles, to any Shareholder whose address as registered
in the Register (or as designated in writing for the receipt of notices and other documents)
is located in the State of Israel; and |
| 131.2. | one
daily newspaper in New York, NY, United States, and in one international wire service shall
be deemed to be notice of such meeting duly given, for the purposes of these Articles, to
any shareholder whose address as registered in the Register (or as designated in writing
for the receipt of notices and other documents) is located outside the State of Israel. |
INSURANCE,
INDEMNITY AND EXCULPATION
132. | Subject
to the provisions of the Companies Law, the Company shall be entitled to enter into a contract
to insure all or part of the liability of an Office Holder of the Company, imposed on him
in consequence of an act which he has performed by virtue of being an Office Holder, in respect
of any of the following: |
| 132.1. | The
breach of a duty of care to the Company or to any other Person; |
| 132.2. | The
breach of a fiduciary duty to the Company, provided that the Office Holder acted in good
faith and had reasonable grounds for believing that the action would not adversely affect
the best interests of the Company; |
| 132.3. | A
pecuniary liability imposed on him in favor of any other person in respect of an act done
in his capacity as an Office Holder. |
| 132.4. | Any
other circumstances arising under the law with respect to which the Company may, or will
be able to, insure an Office Holder. |
133. | Subject
to the provisions of the Companies Law, the Company shall be entitled to indemnify an Office
Holder of the Company, to the fullest extent permitted by applicable law. Subject to the
provisions of the Companies Law, including the receipt of all approvals as required therein
or under any applicable law, the Company may resolve retroactively to indemnify an Office
Holder with respect to the following liabilities and expenses, provided, in each of the below
cases, that such liabilities or expenses were incurred by such Office Holder in such Office
Holder’s capacity as an Office Holder of the Company: |
| 133.1. | a
monetary liability imposed on him in favor of a third party in any judgment, including any
settlement confirmed as judgment and an arbitrator’s award which has been confirmed
by the court, in respect of an act performed by the Office Holder by virtue of the Office
Holder being an Office Holder of the Company; provided, however, that: (a) any indemnification
undertaking with respect to the foregoing shall be limited (i) to events which, in the opinion
of the Board of Directors, are foreseeable in light of the Company’s actual operations
at the time of the granting of the indemnification undertaking, and (ii) to an amount or
by criteria determined by the Board of Directors to be reasonable in the given circumstances;
and (b) the events that in the opinion of the Board of Directors are foreseeable in light
of the Company’s actual operations at the time of the granting of the indemnification
undertaking are listed in the indemnification undertaking together with the amount or criteria
determined by the Board of Directors to be reasonable in the given circumstances; |
| 133.2. | reasonable
litigation expenses, including legal fees, paid for by the Office Holder, in an investigation
or proceeding conducted against such Office Holder by an agency authorized to conduct such
investigation or proceeding, and which investigation or proceeding: (i) concluded without
the filing of an indictment (as defined in the Companies Law) against such Office Holder
and without there having been a monetary liability imposed against such Office Holder in
lieu of a criminal proceeding (as defined in the Companies Law); (ii) concluded without the
filing of an indictment against such Office Holder but with there having been a monetary
liability imposed against such Office Holder in lieu of a criminal proceeding for an offense
that does not require proof of criminal intent; or (iii) involves financial sanction; |
| 133.3. | reasonable
litigation expenses, including legal fees, paid for by the Office Holder, or which the Office
Holder is obligated to pay under a court order, in a proceeding brought against the Office
Holder by the Company, or on its behalf, or by a third party, or in a criminal proceeding
in which the Office Holder is found innocent, or in a criminal proceeding in which the Office
Holder was convicted of an offense that does not require proof of criminal intent; and |
| 133.4. | any
other event, occurrence or circumstances in respect of which the Company may lawfully indemnify
an Office Holder of the Company (including, without limitation, indemnification with respect
to the matters referred to under Section 56h(b)(1) of the Israeli Securities Law 5728-1968,
as amended. |
| 133.5. | The
Company may undertake to indemnify an Office Holder as aforesaid:
(i) prospectively, provided that the undertaking is limited to categories of events which
in the opinion of the Board of Directors can be foreseen when the undertaking to indemnify
is given, and to an amount set by the Board of Directors as reasonable under the circumstances,
and (ii) retroactively. |
134. | Subject
to the provisions of the Companies Law including the receipt of all approvals as required
therein or under any applicable law, the Company may, to the maximum extent permitted by
the Companies Law, exempt and release, in advance, any Office Holder from any liability for
damages arising out of a breach of a duty of care towards the Company. |
| 135.1. | Any
amendment to the Companies Law adversely affecting the right of any Office Holder to be indemnified
or insured pursuant to Articles 132, 133 and 134 and any amendments to Articles 132, 133
and 134 shall be prospective in effect, and shall not affect the Company’s obligation
or ability to indemnify or insure an Office Holder for any act or omission occurring prior
to such amendment, unless otherwise provided by applicable law. |
| 135.2. | The
provisions of Articles 132, 133 and 134 are not intended, and shall not be interpreted so
as to restrict the Company, in any manner, in respect of the procurement of insurance and/or
in respect of indemnification and/or exculpation, in favor of any person who is not an Office
Holder, including, without limitation, any employee, agent, consultant or contractor of the
Company who is not an Office Holder; and/or any Office Holder to the extent that such insurance
and/or indemnification is not specifically prohibited under law. |
WINDING-UP
AND REORGANIZATION
136. | Should
the Company be wound up and the assets of the Company made available for distribution among
Shareholders be insufficient to repay all of the Company’s paid-up capital, such assets
shall be divided in a manner whereby the losses shall, as far as possible, be borne by the
Shareholders pro rata to the nominal value of the paid-up capital on the shares held by each
of them, and, if at the time of the winding-up, the property of the Company available for
distribution among the Shareholders should exceed the amount sufficient for the repayment
of the full nominal value of the paid-up capital at the time of commencement of the winding-up,
the surplus shall be distributed to the Shareholders pro rata to the paid-up capital held
by each of them. |
137. | Upon
the sale of the Company’s assets, the Board of Directors may, or in the case of a liquidation,
the liquidators may, if authorized to do so by a Resolution of the Company, accept fully
or partly paid-up shares, or securities of another company, Israeli or non-Israeli, whether
in existence at such time or about to be formed, in order to purchase the property of the
Company, or part thereof, and to the extent permitted under the Companies Law, the Board
of Directors may (or in the case of a liquidation, the liquidators may) distribute the aforesaid
shares or securities or any other property of the Company among the Shareholders without
realizing the same, or may deposit the same in the hands of trustees for the Shareholders,
and the General Meeting by a Resolution may decide, subject to the provisions of the Companies
Law, on the distribution or allotment of cash, shares or other securities, or the property
of the Company and on the valuation of the aforesaid securities or property at such price
and in such manner as the Shareholders at such General Meeting shall decide, and all of the
Shareholders shall be obliged to accept any valuation or distribution determined as aforesaid
and to waive their rights in this regard, except, in a case in which the Company is about
to be wound-up and is in the process of liquidation, for those legal rights (if any) which,
according to the provisions of the Companies Law, may not be changed or modified. |
* * *
Changes to the Articles
of Association, approved by the shareholders on July 29, 2020
AMENDMENTS
TO CURRENT ARTICLES OF ASSOCIATION
Article
6 of the Company’s Articles of Association will read as follows:
The
Company’s share capital shall be NIS 1,500,000 divided as follows:
The
share capital of the Company shall consist of NIS 1,500,000 divided into 150,000,000 Ordinary Shares, of a nominal value of NIS 0.01
each (the “Ordinary Shares”).
Changes
to the Articles of Association, approved by the shareholders on July 7, 2022
AMENDMENTS
TO CURRENT ARTICLES OF ASSOCIATION
Article
6 of the Company’s Articles of Association will read as follows:
The Company’s share capital shall be NIS 2,000,000
divided as follows:
The
share capital of the Company shall consist of NIS 2,000,000 divided into 200,000,000 Ordinary Shares, of a nominal value of NIS 0.01
each (the “Ordinary Shares”).
Changes
to the Articles of Association (the “Articles”), approved by the shareholders on October 12, 2023
AMENDMENTS
TO CURRENT ARTICLES OF ASSOCIATION
1. | The
definition of the “Company” as defined in 1.1 of the Articles shall be changed such that the Company name in the Articles
shall be “Notable Labs, Ltd.” or “נוטבל לאבס, בע"מ”. |
2. | Article
6 of the Articles shall be amended and restated in its entirety with the following: |
The
share capital of the Company shall consist of NIS 12,000,000 divided into 34,285,714 Ordinary Shares, of a nominal value of NIS 0.35
each (the “Ordinary Shares”).
3. | Article
58 of the Articles shall be amended and restated in its entirety with the following: |
No
business shall be conducted at a General Meeting unless a quorum is present, and no resolution shall be passed unless a quorum is present
at the time the resolution is voted on. Except in cases where it is otherwise stipulated, a quorum shall be constituted when there are
personally present, or represented by proxy, at least one (1) Shareholder who hold or represents at least 1/3 (33.33%) of the voting
rights of the Company.
Exhibit
5.1
October
17, 2023
Notable
Labs, Ltd.
320 Hatch Drive
Foster City, CA 94404
Re:
Registration Statement on Form S-3
Ladies
and Gentlemen:
We
have acted as Israeli counsel to Notable Labs, Ltd., a company organized under the laws of the State of Israel (the “Company”),
in connection with its filing of a registration statement on Form S-3 (the “Registration Statement”) under the Securities
Act of 1933, as amended (the “Securities Act”), with the U.S. Securities and Exchange Commission (the “Commission”),
which registers the offer, issuance and sale by the Company, from time to time, of up to $100 million, in the aggregate, of any
one or more of the following types of securities, individually or in units:
|
(a) |
ordinary
shares, par value NIS 0.35 each, of the Company (“Ordinary Shares” or “Shares”); |
|
|
|
|
(b) |
warrants
to purchase Ordinary Shares (“Warrants”); or |
|
|
|
|
(c) |
units
comprised of one or more of the other securities that may be offered under the Registration Statement (the “Units”)
(collectively, the Shares, Warrants and Units are referred to as the “Securities”). |
This
opinion letter is furnished to you at your request to enable you to fulfill the requirements of Item 601(b)(5) of Regulation S-K under
the Securities Act, in connection with the filing of the Registration Statement.
In
connection herewith, we have examined the originals, or photocopies or copies, certified or otherwise identified to our satisfaction,
of: (i) the form of the Registration Statement, to which this opinion letter is attached as an exhibit; (ii) a copy of the articles of
association of the Company, as currently in effect (the “Articles”); (iii) minutes of the meeting of the board
of directors of the Company (the “Board”) at which the filing of the Registration Statement and the actions
to be taken in connection therewith were approved; and (iv) such other corporate records, agreements, documents and other instruments,
and such certificates or comparable documents of public officials and of officers and representatives of the Company as we have deemed
relevant and necessary as a basis for the opinions hereafter set forth. We have also made inquiries of such officers and representatives
as we have deemed relevant and necessary as a basis for the opinions hereafter set forth.
In
such examination, we have assumed the genuineness of all signatures, the legal capacity of all natural persons, the authenticity of all
documents submitted to us as originals, the conformity to original documents of all documents submitted to us as certified, confirmed
as photostatic copies and the authenticity of the originals of such latter documents. As to all questions of fact material to these opinions
that have not been independently established, we have relied upon certificates or comparable documents of officers and representatives
of the Company.
We
have also assumed the truth of all facts communicated to us by the Company and that all minutes of meetings of the Board that have been
provided to us are true and accurate and have been properly prepared in accordance with the Articles and all applicable laws. We have
assumed, in addition, that at the time of the execution and delivery of any definitive purchase, underwriting or similar agreement between
the Company and any third party pursuant to which any of the Securities may be issued (a “Securities Agreement”),
the Securities Agreement will be the valid and legally binding obligation of such third party, enforceable against such third party in
accordance with its terms. We have further assumed that at the time of the issuance and sale of any of the Securities, the terms of the
Securities, and their issuance and sale, will have been established so as not to violate any applicable law or result in a default under
or breach of any agreement or instrument binding upon the Company and so as to comply with any requirement or restriction imposed by
any court or governmental body having jurisdiction over the Company.
Based
upon and subject to the foregoing, we are of the opinion that:
|
1. |
With
respect to the Shares, assuming (a) the taking of all necessary corporate action to authorize and approve the issuance of any Shares,
the terms of the offering thereof and related matters (for purposes of this paragraph 1, the “Authorizing Resolutions”),
(b) the effectiveness of the Registration Statement, and any amendments thereto (including any post-effective amendments), and that
such effectiveness shall not have been terminated or rescinded, (c) the delivery and filing of an appropriate prospectus supplement
with respect to the offering of the Shares in compliance with the Securities Act and the applicable rules and regulations thereunder,
(d) approval by the Board of, and entry by the Company into, and performance by the Company under, any applicable Securities Agreement,
in the form filed as an exhibit to the Registration Statement, any post-effective amendment thereto or to Current Reports on Form
8-K, pursuant to which the Shares may be issued and sold, and (e) receipt by the Company of the consideration for the Shares as provided
for in the Authorizing Resolutions and in accordance with the provisions of any such Securities Agreement and the applicable convertible
Securities, if any, pursuant to which the Shares may be issued, such Shares, including any Ordinary Shares issued upon exercise or
conversion of any Securities, will be validly issued, fully paid and non-assessable. |
|
|
|
|
2. |
With
respect to the Warrants, assuming the (a) taking of all necessary corporate action to authorize and approve the issuance and terms
of any Warrants, the terms of the offering thereof and related matters (for purposes of this paragraph 2, the “Authorizing
Resolutions”), (b) the effectiveness of the Registration Statement, and any amendments thereto (including any post-effective
amendments), and that such effectiveness shall not have been terminated or rescinded, (c) the due authorization, execution and delivery
of (i) the warrant agreement to be dated on or about the date of the first issuance of the applicable Warrants thereunder, by and
between the Company and a warrant agent to be selected by the Company (each, a “Warrant Agreement”) and
(ii) any certificates relating to the Warrants, (d) the delivery and filing of an appropriate prospectus supplement with respect
to the offering of the Warrants in compliance with the Securities Act and the applicable rules and regulations thereunder, (e) entry
by the Company into, and performance by the Company under, any applicable Warrant Agreement, in the form filed as an exhibit to the
Registration Statement, any post-effective amendment thereto or to a Current Reports on Form 8-K, pursuant to which the Warrants
may be issued and sold, (f) due establishment by all necessary corporate action and in conformity with the Articles (as then in effect),
the Warrant Agreement and any warrant certificates, of the terms of the Warrants and of their issuance and sale, (g) due execution
and counter-signature, in accordance with the provisions of the Warrant Agreement, and due issuance, sale and delivery, in accordance
with the provisions of any such Warrant Agreement, the Registration Statement and the prospectus included therein, of the Warrants
and (h) receipt by the Company of the consideration for the Warrants as provided for in the Authorizing Resolutions and in accordance
with the provisions of any such Securities Agreement, such Warrants, including any Ordinary Shares issued upon exercise or conversion
of any Warrants, will constitute valid and legally binding obligations of the Company. |
|
3. |
With
respect to the Units, assuming the (a) taking of all necessary corporate action to authorize and approve the issuance and the terms
of the Units and any Securities that are components to the units, the terms of the offering thereof and related matters (for purposes
of this paragraph 3, the “Authorizing Resolutions”), (b) the effectiveness (without termination or rescindment)
of the Registration Statement, as finally amended (including any post-effective amendments), under the Securities Act, (c) the due
authorization, execution and delivery of (i) the Unit Agreement to be dated on or about the date of the first issuance of the applicable
Units thereunder, by and between the Company and a rights agent to be selected by the Company (a “Units Agreement”)
and (ii) any certificates relating to the Units, (d) the delivery and filing of an appropriate prospectus supplement with respect
to the offering of the Units in compliance with the Securities Act and the applicable rules and regulations thereunder, (e) approval
by the Board of, and entry by the Company into, and performance by the Company under, any applicable Units Agreement, in the form
filed as an exhibit to the Registration Statement, any post-effective amendment thereto or to a Current Reports on Form 8-K, pursuant
to which the Units may be issued and sold, (f) due establishment by all necessary corporate action and in conformity with the Articles
(as then in effect) and the Units Agreement and any rights certificates, of the terms of the Units and of their issuance and sale,
(g) due execution and counter-signature, in accordance with the provisions of the Unit Agreement, and due issuance, sale and delivery,
in accordance with the provisions of any such Units Agreement, the Registration Statement and the prospectus included therein, of
the Units and (h) receipt by the Company of the consideration for the Units as provided for in the Authorizing Resolutions and in
accordance with the provisions of any such Units Agreement, such Units will constitute valid and legally binding obligations of the
Company. |
You
have informed us that you intend to issue the Securities from time to time on a delayed or continuous basis, and this opinion is limited
to the laws, including the rules and regulations, as in effect on the date hereof. We understand that prior to issuing any Securities
you will afford us an opportunity to review the corporate approval documents and operative documents pursuant to which such Securities
are to be issued (including the Authorizing Resolutions, a Securities Agreement (if applicable) and an appropriate prospectus supplement),
and we will file such supplement or amendment to this opinion (if any) as we may reasonably consider necessary or appropriate by reason
of the terms of such Securities.
With
respect to our opinion as to the Shares, we have assumed that, at the time of issuance and sale and to the extent any such issuance would
exceed the maximum share capital of the Company currently authorized, the number of Ordinary Shares that the Company is authorized to
issue shall have been increased in accordance with the Company’s Articles and as described in the Registration Statement such that
a sufficient number of Ordinary Shares are authorized and available for issuance under the Articles.
Members
of our firm are admitted to the Bar in the State of Israel, and we do not express any opinion as to the laws of any other jurisdiction.
This opinion is limited to the matters stated herein and no opinion is implied or may be inferred beyond the matters expressly stated.
We
consent to the filing of this opinion as an exhibit to the Registration Statement and to the reference to our firm appearing under the
caption “Legal Matters” and “Enforceability of Civil Liabilities and Other Matters” in the prospectus forming
part of the Registration Statement. In giving this consent, we do not thereby admit that we are within the category of persons whose
consent is required under Section 7 of the Securities Act, the rules and regulations of the Commission promulgated thereunder or Item
509 of the Commission’s Regulation S-K under the Securities Act.
This
opinion letter is rendered as of the date hereof and we disclaim any obligation to advise you of facts, circumstances, events or developments
that may be brought to our attention after the effective date of the Registration Statement that may alter, affect or modify the opinions
expressed herein.
|
Very truly
yours, |
|
|
|
Meitar | Law
Offices |
Exhibit
5.2
October
17, 2023
Notable
Labs, Ltd.
Registration
Statement on Form S-3
Ladies
and Gentlemen:
We
have acted as U.S. counsel for Notable Labs, Ltd., an Israeli corporation (the “Company”), in connection with the preparation
and filing with the Securities and Exchange Commission (the “Commission”) of a Registration Statement on Form S-3 (the “Registration
Statement”) under the Securities Act of 1933, as amended (the “Securities Act”), relating to the registration under
the Securities Act and the proposed issuance and sale from time to time pursuant to Rule 415 under the Securities Act of (i) ordinary
shares of the Company, par value NIS 0.35 per share (“Ordinary Shares”), (ii) warrants to purchase Ordinary Shares (“Warrants”)
and (iii) units comprised of a combination of Ordinary Shares and Warrants (“Units” and, collectively with Ordinary Shares
and Warrants, the “Securities”).
In
connection with this opinion, we have examined originals, or copies certified or otherwise identified to our satisfaction, of such documents,
corporate records, certificates of corporate officers and government officials and other documents as we have deemed necessary or appropriate
for the purposes of this opinion, including the Registration Statement. As to various questions of fact material to this opinion, we
have relied upon representations of officers or directors of the Company and documents furnished to us by the Company without independent
verification of their accuracy. We have also assumed the genuineness of all signatures, the legal capacity and competency of all natural
persons, the authenticity of all documents submitted to us as originals and the conformity to authentic original documents of all documents
submitted to us as copies.
Based
upon and subject to the foregoing, and assuming that: (i) the Registration Statement and any supplements and amendments thereto (including
post-effective amendments) will have become effective and will comply with all applicable laws; (ii) the Registration Statement and any
supplements and amendments thereto (including post-effective amendments) will be effective and will comply with all applicable laws at
the time the Securities are offered or issued as contemplated by the Registration Statement; (iii) a prospectus supplement will have
been prepared and filed with the Commission describing the Securities offered thereby and will comply with all applicable laws; (iv)
all Securities will be issued and sold in compliance with all applicable Federal and state securities laws and in the manner stated in
the Registration Statement and the appropriate prospectus supplement; (v) none of the terms of any Security to be established subsequent
to the date hereof, nor the issuance and delivery of such Security, nor the compliance by the Company with the terms of such Security
will violate any applicable law or will result in a violation of any provision of any instrument or agreement then binding upon the Company
or any restriction imposed by any court or governmental body having jurisdiction over the Company; (vi) a definitive purchase, underwriting,
or similar agreement and any other necessary agreement with respect to any Securities offered or issued will have been duly authorized
and validly executed and delivered by the Company and the other parties thereto; (vii) any warrant agreement relating to the Warrants
and any unit agreement relating to the Units will be governed by the laws of the State of New York; and (viii) any Securities issuable
upon conversion, exchange or exercise of any Security being offered or issued will be duly authorized, created and, if appropriate, reserved
for issuance upon such conversion, exchange or exercise, we are of opinion as follows:
| (1) | with
respect to the Warrants, when (A) the Board of Directors of the Company or a duly constituted
and acting committee thereof (such Board of Directors or committee being hereinafter referred
to as the “Board”) has taken all necessary corporate action to approve the creation
of and the issuance and terms of the Warrants, the terms of the offering thereof and related
matters, (B) a warrant agreement or agreements relating to the Warrants have been duly authorized
and validly executed and delivered by the Company, the warrant agent appointed by the Company
and each other party thereto and (C) the Warrants or certificates representing the Warrants
have been duly executed, countersigned, registered and delivered in accordance with the appropriate
warrant agreement or agreements and the applicable definitive purchase, underwriting or similar
agreement approved by the Board, upon payment of the consideration therefor provided for
therein, such Warrants will constitute valid and binding obligations of the Company, enforceable
against the Company in accordance with their terms (subject to applicable bankruptcy, insolvency,
reorganization, moratorium, fraudulent transfer and other similar laws affecting creditors’
rights generally from time to time in effect and to general principles of equity, including
concepts of materiality, reasonableness, good faith and fair dealing, regardless of whether
considered in a proceeding in equity or at law); and |
| | |
| (2) | with
respect to the Units, when (A) the Board has taken all necessary corporate action to approve
the creation of and the issuance and terms of the Units, the terms of the offering thereof
and related matters, (B) a unit agreement or agreements relating to the Units have been duly
authorized and validly executed and delivered by the Company and each other party thereto
and (C) the Units or certificates representing the Units have been duly executed, countersigned,
registered and delivered in accordance with the appropriate unit agreement or agreements
and the applicable definitive purchase, underwriting or similar agreement approved by the
Board, upon payment of the consideration therefor provided for therein, such Units will constitute
valid and binding obligations of the Company, enforceable against the Company in accordance
with their terms (subject to applicable bankruptcy, insolvency, reorganization, moratorium,
fraudulent transfer and other similar laws affecting creditors’ rights generally from
time to time in effect and to general principles of equity, including concepts of materiality,
reasonableness, good faith and fair dealing, regardless of whether considered in a proceeding
in equity or at law). |
We
express no opinion herein as to any provision of the Warrants, Units, any warrant agreement relating to the Warrants or any unit agreement
relating to the Units that (i) relates to the subject matter jurisdiction of any Federal court of the United States of America, or any
Federal appellate court, to adjudicate any controversy related to the Warrants or Units, (ii) contains a waiver of an inconvenient forum,
(iii) relates to the waiver of rights to jury trial or (iv) provides for indemnification, contribution or limitations on liability. We
also express no opinion as to (i) the enforceability of the provisions of the Warrants, any warrant agreement relating to the Warrants,
the Units or any unit agreement relating to the Units to the extent that such provisions constitute a waiver of illegality as a defense
to performance of contract obligations or any other defense to performance which cannot, as a matter of law, be effectively waived or
(ii) whether a state court outside the State of New York or a Federal court of the United States would give effect to the choice of New
York law provided for therein.
Courts
in the United States have not customarily rendered judgments for money damages denominated in any currency other than United States dollars.
Section 27(b) of the Judiciary Law of the State of New York provides, however, that a judgment or decree in an action based upon an obligation
denominated in a currency other than United States dollars shall be rendered in the foreign currency of the underlying obligation and
converted into United States dollars at the rate of exchange prevailing on the date of the entry of the judgment or decree. We express
no opinion as to whether a Federal court would render a judgment other than in United States dollars.
We
are admitted to practice only in the State of New York and express no opinion as to matters governed by any laws other than the laws
of the State of New York and the Federal laws of the United States of America. In particular, we do not purport to pass on any matter
governed by the laws of Israel. Insofar as the opinions expressed herein relate to or depend upon matters governed by the laws of other
jurisdictions as they relate to the Company, we have relied upon and assumed the correctness of, without independent investigation, the
opinion of Meitar Law Offices, Israeli counsel to the Company, which is being delivered to you and filed with the Commission as an exhibit
to the Registration Statement.
We
understand that we may be referred to under the heading “Legal Matters” in the prospectus and in a supplement to the prospectus
forming a part of the Registration Statement, and we hereby consent to such use of our name in said Registration Statement and to the
use of this opinion for filing with said Registration Statement as Exhibit 5.2 thereto. In giving this consent, we do not hereby admit
that we are within the category of persons whose consent is required under Section 7 of the Securities Act or the Rules and Regulations
of the Commission promulgated thereunder.
|
Very
truly yours, |
|
|
|
/s/
Cravath, Swaine & Moore LLP |
Notable
Labs, Ltd.
320
Hatch Drive
Foster
City, CA 94404
Exhibit
23.3
CONSENT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We
hereby consent to the incorporation by reference in this Registration Statement on Form S-3 of Notable Labs, Ltd. of our report
dated March 14, 2023 relating to the financial statements, which appears in Vascular Biogenics Ltd.’s
Annual Report on Form 10-K for the year ended December 31, 2022. We also consent to the reference to us under the heading “Experts”
in such Registration Statement.
Tel-Aviv, Israel |
/s/ Kesselman & Kesselman |
October 17, 2023 |
Certified Public Accountants (Isr.) |
|
A member firm of PricewaterhouseCoopers International Limited |
Exhibit
23.4
CONSENT
OF INDEPENDENT AUDITOR
We
consent to the incorporation by reference in the Registration Statement on Form S-3 of our report dated May 11, 2023, relating
to the financial statements of Notable Labs, Inc. appearing in the Registration Statement No. 333-271826 on Form S-4 of Vascular Biogenics
Ltd. We also consent to the reference to us under the heading “Experts” in such Registration Statement.
/s/
Deloitte & Touche LLP
San
Francisco, California
October
17, 2023
Exhibit
107
Calculation
of Filing Fee Tables
S-3
(Form
Type)
Notable
Labs, Ltd.
(Exact
Name of Registrant as Specified in its Charter)
Table
1: Newly Registered and Carry Forward Securities
| |
Security Type | |
Security Class Title | |
Fee Calculation or Carry Forward Rule | | |
Amount Registered | | |
Proposed Maximum Offering Price Per Unit | | |
Maximum Aggregate Offering Price | | |
Fee Rate | | |
Amount of Registration Fee | | |
Carry Forward Form Type | | |
Carry Forward File Number | | |
Carry Forward Initial effective date | | |
Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward | |
Newly Registered Securities |
Fees to Be Paid | |
Equity | |
Ordinary shares, par value NIS 0.35 per share | |
| 457 | (o) | |
| (1 | ) | |
| (2 | ) | |
| (2 | ) | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| |
Other | |
Warrants | |
| 457 | (o) | |
| (1 | ) | |
| (2 | ) | |
| (2 | ) | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| |
Other | |
Units | |
| 457 | (o) | |
| (1 | ) | |
| (2 | ) | |
| (2 | ) | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| |
Unallocated (Universal) Shelf | |
N/A | |
| 457 | (o) | |
$ | 100,000,000 | | |
| N/A | | |
$ | 100,000,000 | | |
| 0.00014760 | | |
$ | 14,760 | | |
| | | |
| | | |
| | | |
| | |
Fees Previously Paid | |
| |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Carry Forward Securities |
Carry Forward Securities | |
| |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| |
Total Offering Amounts | | |
| | | |
$ | 100,000,000 | | |
| | | |
$ | 14,760 | | |
| | | |
| | | |
| | | |
| | |
| |
Total Fees Previously Paid | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| |
Total Fee Offsets | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| |
Net Fee Due | | |
| | | |
| | | |
| | | |
$ | 14,760 | | |
| | | |
| | | |
| | | |
| | |
(1)
This registration statement covers offers, sales and distributions of an indeterminate number or aggregate principal amount of the registered
securities which the registrant may from time to time issue at indeterminate prices. The aggregate maximum offering price of all securities
covered by this registration statement will not exceed $100,000,000. The securities covered by this registration statement may be sold
separately or as units with other classes of the registered securities.
(2)
The registrant will determine the proposed maximum offering price per security from time to time in connection with the issuance of
the registered securities. The proposed maximum aggregate offering price for each class is omitted pursuant to Instruction
2.A.iii.b. to the Calculation of Filing Fee Tables and Related Disclosure on Item 16(b) of Form S-3 under the Securities and
Exchange Act of 1933, as amended.
Vascular Biogenics (NASDAQ:VBLT)
過去 株価チャート
から 4 2024 まで 5 2024
Vascular Biogenics (NASDAQ:VBLT)
過去 株価チャート
から 5 2023 まで 5 2024